Author: "L G Zhukova" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"L G Zhukova"' showing total 104 results

Start Over Author "L G Zhukova"

104 results on '"L G Zhukova"'

1. Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Author: L G Zhukova, I P Ganshina, E I Khatkova, T E Tikhomirova, and O E Kondratyeva
Subjects: trastuzumab, breast cancer, her2-possitive, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: According to the results of the conducted studies in the early 2000’s, adjuvant trastuzumab for 1 year has been admitted the gold standard since 2006. However, the high cost of treatment and the increasing of the risk of cardiotoxicity have led to new clinical trials concerning the short-course trastuzumab regimen. The study deals with the results of the number of the largest randomized trials associated with the comparison of 6 months (the PHARE trial and the HORG study), 9 weeks (the Short-HER study and the SOLD study) and 12 months duration of adjuvant trastuzumab therapy in combination with chemotherapy in patients with HER2-possitive early breast cancer. Today, none of the studies has shown statistically significant evidence of the possibility to reduce the duration of adjuvant trastuzumab therapy.
Published: 2018
Full Text: View/download PDF

2. Ribociclib in 1st line HR+ breast cancer treatment

Author: L G Zhukova, I P Ganshina, O O Gordeeva, and E V Lubennikova
Subjects: breast cancer, first line, cdk4/6 inhibitors, ribociclib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Breast cancer is a leading oncologic disease among women worldwide. Though the achieved results in treating patients with luminal subtypes are high, there is a great demand on new approaches in this field. This article highlights the new CDK4/6 inhibitor ribociclib as well as presents clinical cases from the own clinical practice obtained during phase IIIb COMPLEEMENT trial.
Published: 2018
Full Text: View/download PDF

3. Ramucirumab therapy in patients with advanced gastric cancer: discussion of a case series

Author: R V Orlova, L G Zhukova, I P Ganshina, D Yu Yukalchuk, D M Ponomarenko, N P Beliak, O O Gordeeva, S P Erdniev, A A Minasyan, A A Dashkova, E R Sopiya, E A Sholokhova, and A B Gurochkin
Subjects: gastric cancer, ramucirumab, paclitaxel, case reports, vascular endothelial growth factor receptor-2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Background. Gastric cancer is the fifth most common malignancy worldwide with diagnosis often occurring at an advanced stage. For the majority of advanced gastric cancer patients, chemotherapy typically is used as first-line treatment, although many patients will also require second-line treatment. Ramucirumab (Cyramza®, Eli Lilly and Company, Indianapolis, Indiana, USA) recently has received worldwide and United States Food and Drug Administration approval for gastric cancer in the second-line setting. Case reports. A series of five advanced gastric cancer cases is presented, outlining each patient’s diagnosis and treatment. All patients were treated with intravenous ramucirumab (8 mg/kg on days 1 and 15) plus paclitaxel (80 or 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle) after disease progression on or after first-line chemotherapy. Patient outcomes are described including an outline of treatment-related adverse events and quality of life. All patients were able to achieve a clinical response and stable disease. Conclusion. Our case series demonstrates that ramucirumab, in conjunction with paclitaxel, is an effective and well-tolerated treatment option for advanced gastric cancer patients who have disease progression following first-line chemotherapy.
Published: 2018

4. Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0

Author: O A Pavlikova, I V Poddubnaya, I V Kolyadina, A Guseynovich Abdullaev, D V Komov, T Yu Danzanova, G T Sinyukova, N A Kozlov, I P Ganshina, L G Zhukova, G S Aliyeva, R A Kerimov, and O O Gordeeva
Subjects: pcr, breast cancer, biological subtypes, tumor response from systemic therapy, preoperative systemic therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: The aim. To study the clinical and radiological evaluation of the effectiveness of preoperative systemic therapy and to compare the results of macroscopic and microscopic evaluation of response in different biological subtypes of breast cancer (BC). Materials and methods. The study included 213 women with breast cancer stages T1-3N0-1M0, treated by preoperative systemic therapy and radical surgery with morphological evaluation of the response in the N.N.Blokhin National Research Oncology Center from 2004 to 2017. All patients had clinical and radiological examination (mammography and ultrasound) before and after neoadjuvant systemic therapy. The rate of morphological response was assessed in different biological subtypes and the rate of pCR was compared with the clinical, radiologic and macroscopic morphological data, statistical analyses was made by SPSS 20.0, the differences were considered reliable at p
Published: 2017

5. Dermatomyositis and polymyositis in breast cancer patients: a case reports

Author: I P Ganshina, L G Zhukova, E Z Burnevitch, O O Gordeeva, and O E Kondratieva
Subjects: dermatomyositis, polymyositis, breast cancer, paraneoplastic syndrome, anti-her2 therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Dermatomyositis and polymyositis are an autoimmune disease which is characterized by proximal skeletal muscle weakness, muscle inflammation and associated with a variety of skin manifestations. Both autoimmune conditions are mainly observed as an independent disease, though an association between dermato- and polymyositis and malignancy were described. Case reports of two patients are presented, in one of which dermatomyositis and breast cancer were manifested simultaneously, in the other - the development of polymyositis preceded the recurrence of the disease after a long-term remission. Also diagnostic and therapeutic options of both conditions are shown.
Published: 2018

6. Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case

Author: I V Kolyadina, I P Ganshina, L G Zhukova, A G Abdullaev, Yu Yu Andreeva, T Yu Danzanova, G T Sinyukova, D V Komov, N A Kozlov, D A Filonenko, O O Gordeeva, and E V Lubennikova
Subjects: breast cancer, her2+ biological subtype, soft tissue metastases gluteal region, anti-her2 therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Soft tissue metastases of the gluteal region in solid tumors observed very rarely. We described a unique clinical case of gluteal soft tissue metastases in HER2+ breast cancer; through close collaboration were able to confirm the progression of the breast cancer and plan the treatment strategy based on clinical data and biological subtype of breast cancer.
Published: 2017

7. Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype

Author: E V Karabina and L G Zhukova
Subjects: breast cancers with a triple-negative phenotype, triple-negative metastatic breast cancer, eribulin, taxanes, anthracyclines, life expectancy, overall survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Treatment of patients with metastatic breast cancer (BC) with a triple-negative phenotype represents the most difficult challenge for clinicians. The optimal chemotherapy regimens for triple-negative BC (TNBC) have not been determined for a long time. However, in the later periods were found molecular agents of application (6 subtypes of TNBC) for the specific therapeutic agent and were performed many studies and subunit analysis, examined appropriate drugs for TNBC. Cell lines of these subtypes have different anticancer drug sensitivity. The results of further studies of targeted drugs using as monotherapy or in combination with chemotherapy in patients with TNBC, in spite of molecular genetic evidence for their application, have fallen short of expectations, although have shown increase in progression-free survival and overall survival. The development of eribulin (nontaxane microtubule dynamics inhibitor) in 2010 significantly increased the possibility of therapy in patients with locally advanced and metastatic BC who had already received chronic treatment. According to the joint analysis of the randomized phase III EMBRACE trial and Study 301, which included data about 1864 patients, it was demonstrated that eribulin statistically significant improve overall survival compared with other drugs using as monotherapy in the general population and among patients with TNBC [statistically significant differences in overall survival was associated with the subgroup of TNBC in patients who had been treated with eribulin, in comparison with the control arm: 12.9 and 8.2 months, respectively (relative risk 0.74; 95% confidence interval, 0.60 to 0.92, p=0.006)]. This article deals with the own experience of successful and long-term eribulin application in young woman with TN metastatic BC who have had already received chronic treatment.
Published: 2016

8. The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council

Author: V S Andrianova, A V Beliaeva, L V Bolotina, A A Vazhenina, S E Varlamova, V I Vladimirov, L Yu Vladimirova, E K Voznyi, S M Demidov, N V Zhukov, L G Zhukova, E N Imianitov, E I Kovalenko, L M Kogoniia, M M Konstantinova, S A Lan, M R Lichinitser, L V Manziuk, A G Manikhas, G Z Mukhametshina, V F Semiglazov, T Iu Semiglazova, G V Seregina, D L Stroiakovskii, M D Ter-Ovanesov, and A S Chichkanova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2015

9. Antiangiogennaya terapiyapri rake molochnoy zhelezys troynym negativnym fenotipom

Author: L G Zhukova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2011

10. Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu

Author: I V Poddubnaya, M R Lichinitser, S A Tyulyandin, V A Gorbunova, V V Ptushkin, M A Abramov, N S Besova, L V Bolotina, I S Bulavina, O A Gladkov, I S Davidenko, L G Zhukova, I A Koroleva, V O Korolenko, G M Manikhas, A V Snegovoy, Yu I Tyukalov, R Sh Khasanov, and L N Shigapova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2011

11. Opyt dlitel'nogo primeneniya kombinatsii kapetsitabina, lapatiniba i trastuzumabapri HER-2-pozitivnom metastaticheskom rake molochnoy zhelezy. Opisanie klinicheskogo sluchaya

Author: L G Zhukova, M A Okruzhnova, E V Lubennikova, and K R Zeynalova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2011

12. Bevatsizumab v lechenii HER2-negativnogometastaticheskogo raka molochnoy zhelezy:sovremennye dannye ob effektivnostii bezopasnosti

Author: L G Zhukova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2010

13. Sovremennye aspektyprofilaktiki neytropeniipri khimioterapii solidnykh opukholey

Author: M E Abramov and L G Zhukova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2010

14. Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom

Author: L G Zhukova, M E Abramov, Yu V Vakhabova, A N Lud, A A Obukhov, and M R Lichinitser
Subjects: рак молочной железы, химиотерапия, колониестимулирующий фактор, нейпомакс, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Внедрение в клиническую практику большого количества эффективных схем цитостатической терапии позволило, с одной стороны, сделать излечимыми ряд злокачественных опухолей, ранее считавшихся фатальными (герминогенные опухоли, лейкозы, лимфомы и т.д.), с другой – поставило перед клиницистами новые задачи, обусловленные необходимостью улучшения качества жизни больных и преодоления токсичности проводимой терапии.Подавление кроветворной функции костного мозга, приводящее к развитию лейкопении, тромбоцитопении и анемии, является одним из наиболее частых и опасных побочных явлений противоопухолевого лечения.Открытие цитокинов, участвующих в регуляции кроветворения, стало значимым событием в медицинской науке, а рекомбинантные технологии сделали их доступными для клинического использования с целью стимуляции гемопоэза, поврежденного опухолью и/или воздействием цитостатической терапии.
Published: 2009

15. Dlitel'noe i bezopasnoe primenenie Avastina pri metastaticheskom kolorektal'nom rake: klinicheskiy opyt primeneniya

Author: L G Zhukova
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: В настоящее время арсенал противоопухолевых препаратов значительно расширился. При этом произошло не только количественное, но и качественное изменение их спектра. Появились новые классы препаратов, которые значительно отличаются от«классических» цитостатиков как по механизму действия, так и по алгоритму использования и спектру побочных эффектов.Одним из препаратов, относительно недавно вошедших в клиническую практику, является Авастин (бевацизумаб), который в настоящее время зарегистрирован для лечения больных метастатическим раком толстой кишки, молочной железы, немелкоклеточным раком легкого и раком почки. Бевацизумаб не является цитостатическим препаратом в привычном понимании этого слова, так как его действие напрямую направлено не на опухолевые клетки, а на опухолевые сосуды, обеспечивающие оксигенацию и питание опухоли. В связи с этим основным ожидаемым действием бевацизумаба является не достижение непосредственного противоопухолевого эффекта, а длительное поддержание ее в стабильном состоянии, позволяющем пациенту длительно сосуществовать с опухолью. Подобное лечение должно быть продолжительным и непрерывным, что возможно лишь в случае, если препарат является малотоксичным, а возникающие нежелательные явления могут контролироваться без необходимости прерывания курса и/или модификации доз.Важным является и возможность проводить лечение эффективно и безопасно не только в рамках клинических исследований, в которых априори пациент находится под более тщательным наблюдением, но и в широкой клинической практике.Данные об эффективности и безопасности применения бевацизумаба в комбинации с химиотерапией при метастатическом колоректальном раке были получены в так называемом постмаркетинговом исследовании ВЕАТ, показавшем, что эффективность и безопасность препарата в подобных условиях сопоставимы с результатами регистрационных исследований.Опыт применения бевацизумаба в РФ достаточно ограничен, что обосновывает необходимость освещения личного опыта по его использованию. Представляем 2 клинических случая применения Авастина в комбинации с химиотерапией у больных с метастатическим колоректальным раком, подтверждающих возможность его длительного и безопасного использования.
Published: 2009

16. Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO)

Author: L G Zhukova
Subjects: рак молочной железы, химиотерапия, бевацизумаб, паклитаксе, доцетаксел, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Значение таксанов (паклитаксела и доцетаксела) в терапии рака молочной железы (РМЖ) трудно переоценить. В апреле 1994 г. паклитаксел был одобрен к применению у больных с РМЖ, имеющих прогрессирование на стандартной антрациклинсодержащей химиотерапии или в течение 6 мес после окончания антрациклинсодержащей адъювантной терапии. А уже в мае 1996 г. ускоренную регистрацию FDA прошел и другой представитель таксанов – доцетаксел, показав значимое увеличение непосредственной эффективности и выживаемости у больных с РМЖ, имеющих прогрессирование после терапииантрациклинами или во время нее.В 2000 г. были опубликованы результаты 3 рандомизированных исследований (CALGB 9344, NSABP-B28 и исследование клиники M.D. Anderson), продемонстрировавших статистически достоверное увеличение выживаемости без прогрессирования и общей выживаемости (ОВ) у больных с ранним РМЖ, имеющих высокий риск прогрессирования, при проведении 4 дополнительных курсов паклитакселом после стандартных 4 курсов адъювантной химиотерапии АС или FAC.
Published: 2009

17. Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation

Author: M. V. Zhuravleva, K. A. Kokushkin, E. A. Luchinin, E. V. Luchinina, T. R. Kameneva, E. V. Kuznetsova, V. S. Krysanova, E. V. Makarova, and L. G. Zhukova
Subjects: breast cancer, neoadjuvant therapy, neutropenia, empegfilgrastim, filgrastim, Therapeutics. Pharmacology, RM1-950, Economics as a science, HB71-74
Abstract: Objective: to assess budget impact of using empegfilgrastim for the prevention of febrile neutropenia in patients with early and locally advanced human epidermal growth factor receptor 2 positive (HER2+) breast cancer who receive neoadjuvant “docetaxel / carboplatin / trastuzumab + pertuzumab” regimen, considering possible subsequent adjuvant therapy with trastuzumab emtansine or trastuzumab within the Russian healthcare system.Material and methods. We searched and analyzed published clinical, epidemiological and pharmacoeconomic studies as well as regulatory and legal documents. A decision tree model was constructed to reflect the probabilities of switching to different adjuvant therapy regimens depending on the achievement of pathomorphological complete response in patients with early and locally advanced HER2+ breast cancer. The budget impact analysis was carried out comparing two primary prophylactic options, empegfilgrastim and filgrastim.Results. Despite the higher costs of prevention with empegfilgrastim compared to filgrastim (249 vs. 134 thousand rubles), due to the higher rate of achieving a pathomorphological complete response and, accordingly, fewer cases requiring adjuvant therapy with the more expensive trastuzumab emtanzine, savings of 916 thousand rubles per 1 patient per 1 year of therapy are possible. In general, prophylaxis in the target population diagnosed with early and locally advanced HER2+ breast cancer using empegfilgrastim will result in a cost reduction of 9.4 billion rubles per 1 year compared to filgrastim.Conclusion. Empegfilgrastim prophylaxis, despite its higher annual cost, is an efficient option within the Russian healthcare system. In addition to reducing the incidence of febrile neutropenia, the frequency and dose of chemotherapy are preserved, resulting in increased efficacy of the primary therapy.
Published: 2024
Full Text: View/download PDF

18. Multiple primary malignant neoplasms of the mouth and oropharynx

Author: M. A. Kropotov, L. P. Yakovleva, L. G. Zhukova, G. O. Agabekyan, A. V. Khodos, D. A. Safarov, P. A. Gavrishchuk, M. S. Tigrov, and A. S. Vyalov
Subjects: squamous cell carcinoma, head and neck tumors, multiple primary tumors, reconstructive surgery, сo2 laser surgery, transoral surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Introduction. Probability of development of multiple primary tumors in patients who received treatment due to head and neck cancers varies between 5.6 and 35.9 % per different sources. moreover, treatment capabilities are severely limited by postoperative anatomical changes and previous radiation therapy, and the second tumor frequently causes death in these patients.The study objective is to identify the epidemiological features of the development of synchronous and metachronous primary multiple tumors in the head and neck.Materials and methods. The article analyzes data on 103 patients with multiple primary tumors who received treatment due to tumors of the head and neck between 1991 and 2020 at the N.N. Blokhin National medical Research Center of Oncology and A.S. Loginov Moscow Clinical Scientific Center.Results. During the study, typical locations of metachronous tumors in patients who received treatment due to primary malignant tumors of the head and neck were determined, duration of development of multiple primary tumors, treatment methods and survival rates were analyzed.Conclusion. Due to high risk of multiple primary tumors in patients who received treatment due to malignant tumors of the head and neck in the next 5 plus years, it is expedient to observe these patients during their whole lifetime. Considering typical locations of metachronous tumors, examination during dynamic observation should include instrumental methods such as panendoscopy. Surgical treatment should involve the whole spectrum of minimally invasive interventions including CO2 laser surgery and transoral robot-assisted interventions.
Published: 2022
Full Text: View/download PDF

19. Early and late postoperative complications of robot-assisted radical subcutaneous mastectomy with endoprosthesis

Author: G. E. Kvetenadze, E. V. Shivilov, Kh. S. Arslanov, L. G. Zhukova, and I. E. Khatkov
Subjects: breast cancer, robot-assisted radical subcutaneous mastectomy, subcutaneous radical mastectomy, endoprosthetics, complications, Gynecology and obstetrics, RG1-991
Abstract: Over the past two decades, the surgical treatment of breast cancer (BC) has changed from standard radical mastectomies to organ-preserving and reconstructive plastic surgeries using endovideosurgical and robotic technologies. Robot-assisted radical subcutaneous mastectomy, as a minimally invasive method of surgical treatment of BC in the early stages, is recognized as safe and effective.The results of robot-assisted radical subcutaneous mastectomy and radical subcutaneous mastectomy with endoprosthesis in 27 patients with histologically verified BC are presented. A comparative assessment of postoperative complications of robot-assisted radical subcutaneous mastectomy with endoprosthesis and radical subcutaneous mastectomy with endoprosthesis was performed. It was found that the postoperative period in robotic interventions is more favorable, which confirms the low need for analgesics, the absence of signs of the formation of hematomas of the surgical wound, as well as a decrease in the frequency of inflammatory infiltrates and gray soft tissues in the area of the postoperative suture. Performing a robot-assisted radical subcutaneous mastectomy with endoprosthesis can significantly improve the surgical and aesthetic results of BC treatment in the early stages of this disease.
Published: 2022
Full Text: View/download PDF

20. Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy

Author: Yu. A. Vasyuk, E. Y. Shupenina, E. O. Novosel, D. A. Vyzhigin, A. G. Nosova, L. G. Zhukova, D. A. Filonenko, and E. I. Khatkova
Subjects: chemotherapy, cardiotoxicity, left ventricular ejection fraction, left ventricular global longitudinal strain, left ventricular systolic dysfunction, cardioprotection, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Aim. To search early signs of cardiotoxicity in patients receiving anticancer therapy and evaluate the effectiveness of cardioprotection with an angiotensin-converting enzyme inhibitor, beta-blocker and myocardial cytoprotector.Material and methods. The study included 98 patients with high and very high risk of cardiotoxicity according to the Mayo Clinic scale (USA). Cancer patients with hypertension were offered cardioprotective treatment with a fixed-dose combination of perindopril and bisoprolol, and patients with very high risk and concomitant coronary artery disease additionally trimetazidine.The patients were divided into 2 following groups: the experimental group (n=50), where patients were prescribed cardioprotective therapy, and the control group (n=48), which consisted of patients who refused or had contraindications to cardioprotection. All patients underwent an examination, including the collection of complaints and anamnesis, physical examination, electrocardiography and echocardiography with an assessment of left ventricular (LV) global longitudinal strain before chemotherapy and 1, 3, 6, 9 and 12 months after initiation of anticancer therapy.Results. In patients of the control group, by the end of the follow-up, the left atrial volume index and LV end-diastolic volume index significantly increased. In the main group, these indicators did not change significantly. In the control group, by the final visit, the LV ejection fraction significantly decreased in comparison with the initial value and the value in the first group. After 6, 9 and 12 months, there was a significant decrease in the LV global longitudinal strain in the control group, while in the main group this indicator remained within the normal range. The mortality rate in the control group was significantly higher (15% vs 2% in the experimental group). In the experimental group, cardiotoxic complications occurred in 28%, while in the control group — in 78% of patients.Conclusion. The study demonstrated the significant importance of cardiac monitoring and primary drug prevention of cardiotoxicity of anticancer therapy. A sig nificant deterioration in LV systolic function was shown in patients with a high and very high risk of cardiotoxicity who did not receive cardioprotective therapy, while its high efficiency was demonstrated in patients of the experimental group.
Published: 2023
Full Text: View/download PDF

21. ASSOCIATION OF NKT- AND ACTIVATED CD25+ PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS

Author: A. I. Chertkova, E. G. Slavina, T. N. Zabotina, Z. G. Kadagidze, E. K. Shoua, O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Gan’shina, and A. A. Meshcheryakov
Subjects: triple-negative breast cancer, nkt cells, cd25+ lymphocytes, relapse free survival, overall survival, neoadjuvant chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Background. We previously found that a decrease in the number of NKT cells and activated CD 25+ peripheral blood lymphocytes (PBLs) before neoadjuvant chemotherapy was associated with an increased likelihood of disease progression in patients with locally advanced triple-negative breast cancer (TN BC).The purpose of this study was to determine the relationship between the initial number of NKT-and CD 25+ PBLs and relapsefree survival (RFS)/overall survival (OS ) in patients with TN BC who received neoadjuvant chemotherapy with cisplatin and paclitaxel followed by surgery.Material and Methods. The study included patients with stage II and III TN BC. The follow-up time was 36 and 66.9 months. Immediately before chemotherapy, the percentage of CD 3+CD 16+CD 56+ (NKT) -, CD 25+- and CD 8+ PBLs was determined by flow cytometry. Statistical analysis of the data was carried out using the Statistics 7 software package. The Kaplan-Meier method was used to determine the relationship between immunological parameters and RFS/ OS .Results. The decreased level of NKT cells before treatment was associated with a decrease in the 3-year RFS [Me: 20.1 (0.533 and 39.7) months] compared to that observed in patients with higher percentage of these cells than in the control (Me was not achieved). There were no statistically significant differences in the 3-year OS between the groups. The initially reduced number of CD 25+ lymphocytes in comparison with the control was associated with decreased rates of both RFS and OS . The difference in DFS and OS was more significant between the groups of patients who simultaneously had an increased initial number of both NKT and CD 25+ cells and patients in whom both cell populations were below normal levels.Conclusion. The initial (prior to chemotherapy) number of NKT and activated CD 25+ PBLs can apparently be a predictive factor in TN BC patients, who received neoadjuvant chemotherapy with cisplatin and paclitaxel.
Published: 2020
Full Text: View/download PDF

22. Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer

Author: O. O. Gordeeva, I. V. Kolyadina, L. G. Zhukova, I. P. Ganshina, G. V. Vyshinskaya, M. A. Kazantseva, M. V. Sukhova, O. E. Ryabishina, E. V. Lubennikova, D. A. Filonenko, E. I. Chichikov, I. N. Polushkina, E. I. Borisova, A. N. Lud, and A. A. Meshcheryakov
Subjects: triple negative breast cancer, neoadjuvant chemotherapy, pcr, predictors of pcr, prognostic factors, Gynecology and obstetrics, RG1-991
Abstract: Background. Treatment results for the patients with stage II–III triple negative breast cancer (TN BC) have to be improved. Not only the new treatment regimens, but new predictive and prognostic factors should to be developed.Materials and methods. We included 98 patients with stage II–III TN BC in our study. We studied efficacy and safety of PlaTax regimen (cisplatin 75 mg / m2 day 1 + paclitaxel 80 mg / m2 days 1, 8, 15, course every 4 weeks) in this cohort of patients. We assessed pathologic response, survival and factors, which were relevant for predicting response and prognose survival.Results. PlaTax regimen is characterized by high efficacy and tolerable toxicity. Clinical efficacy was 85.8 %, pCR achievement was 60.5 %, tpCR achievement was 58.1 %. The regimen has low haematological toxicity (neutropenia III–IV grades – 4.1 %); the most frequent adverse events were polyneuropathy (18.5 %) and decreased renal function (24.5 %). 3-year progression-free survival was 68.4 %, most of the relapses (92 %) occurred during first 2 years. 3 year overall survival was 77.6 %. The most relevant predictive factor was level of Ki-67 ≥50 % (pCR 38.5 % vs. 68.7 %, p = 0.038). pCR achievement was the most important prognostic factor, resulting in improved 3-year progressionfree survival (44.3 % vs. 89.1 %, p
Published: 2020
Full Text: View/download PDF

23. The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists

Author: L. G. Zhukova and M. A. Mukhina
Subjects: cdk4/6 inhibitors, hormone-positive her2-negative advanced breast cancer, Gynecology and obstetrics, RG1-991
Abstract: The use of CDK4/6 inhibitors in combination with endocrine therapy (aromatase inhibitors and fulvestrant) allowed us to radically change our understanding of opportunities in the treatment of hormone-positive HER2-negative advanced breast cancer and determine optimal therapy sequencing. The results of randomized clinical trials and over 5-years accumulated international experience in the use of CDK4/6 inhibitors in real clinical practice prove that the use of combinations with CDK4/6 inhibitors can achieve significant efficacy results and increase the survival rates when prescribed in 1 and 2 lines of treatment.In this paper, we present the results of a survey conducted in July–October 2019 among 48 oncologists in Moscow, that were asked to choose, in their opinion, the most preferable patient’s profile and molecular and biological features of hormone-positive HER2-negative advanced breast cancer, in which the use of combination therapy with CDK4/6 inhibitors will provide the greatest benefit.Conflict of interest. MD M.A. Mukhina is the medical director of oncology in the Eurasia and Baltic region of Pfizer Innovations Company
Published: 2020
Full Text: View/download PDF

24. Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

Author: O. O. Gordeeva, L. G. Zhukova, I. V. Kolyadina, and I. P. Ganshina
Subjects: breast cancer, metastasis, estrogen receptors, progesterone receptors, her2, sex hormone, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to determining the expression status of estrogen receptor (ER), progesterone receptor (pR) and HER2 only in primary breast cancer tissues, even in the presence of regional metastases.The purpose of the study was to review available data on heterogeneity of ER, pR and HER2/neu expressions in primary breast cancer and regional metastases.Material and methods. We analyzed publications available from pubmed, medline etc. using the keywords «discordance», «breast cancer», «locally advanced», «regional lymph nodes», «ER», «pR», and «HER2».Results. The clinical and prognostic role in assessing the heterogeneity of the receptor status of primary tumors and synchronous regional metastases, as well as the effect of detected discordance on treatment tactics was assessed.Conclusion. Data on the frequency of discordance in hormone receptor status between primary and metastatic breast cancer tumors and its effect on the further prognosis in breast cancer are still contradictory. However, the fact of the presence of such heterogeneity suggests that some patients with affected lymph nodes will have significant benefits from determining the status of steroid hormones and HER2 not only in the primary tumor, but also in the lymph nodes, since it will open up new opportunities for subsequent targeted therapy.
Published: 2019
Full Text: View/download PDF

25. Role of ribociclib in treatment of luminal Her-2-negative mBC with CNS metastases

Author: K. S. Grechukhina, K. A. Vorontsova, D. A. Filonenko, P. S. Tyutyunnik, V. V. Shchadrova, V. V. Glebovskaya, and L. G. Zhukova
Subjects: General Medicine
Abstract: For patients with the metastatic subtype of luminal HER-2-negative (HR+/HER2-) breast cancer (mBC) in the absence of visceral crisis, the gold standard of treatment is a combination of CDK4/6 inhibitors and aromatase inhibitors, regardless of their menopausal status and the sites of metastasis. The effectiveness of this approach was confirmed in the MONARCH, PALOMA, MONALEESA study cycles for the drugs abemaciclib, palbociclib and ribociclib, respectively. Metastasis in the central nervous system (CNS) in breast cancer complicates the treatment of patients and leads to the search for new approaches to the choice of therapy. To date, neurosurgical and radiosurgical techniques are actively used, however, drug therapy still stands for the leading positions. Data on the use of CDK4/6 inhibitors or aromatase inhibitors in patients with CNS metastases are limited. Most studies did not include patients with CNS metastases, only PALOMA-2,3 and MONALEESA-3 studies allowed the inclusion of patients with either “inactive” CNS metastases or after exposure to local treatment methods (for example, radiosurgery, radiotherapy, or surgery). In the study of real clinical practice of combined endocrine therapy with ribociclib (CompLEEment-1) allowed the inclusion of patients with active brain metastases (n = 51), while the subgroup analysis demonstrated the benefits of using a combination of ribociclib and aromatase inhibitors in patients in this difficult clinical situation. In the article, the authors review the available data from randomized clinical trials and real clinical practice, and also illustrate with their own observation.
Published: 2022

26. THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY

Author: A. I. Chertkova, E. G. Slavina, E. K. Shoua, L. G. Zhukova, M. A. Okruzhnova, V. A. Nurtdinova, A. A. Borunova, N. Т. Dzhgamadze, and Z. G. Kadagidze
Subjects: triple negative breast cancer, chemotherapy, peripheral lymphocyte subpopulations, disease progression, overall survival, progression-free survival, Immunologic diseases. Allergy, RC581-607
Abstract: Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of the tumor cells and to influence anti-tumor immune response. Initial state of the immune system and its response to treatment is crucial. Antitumor response involves cells of innate and adaptive immunity (NK, NKT, T cells). These populations are heterogeneous and contain, e.g., cells with antitumor activity and regulatory (suppressor) cells that suppress immune response and promote tumor progression. The aim of this work was to determine the relationship between the initial state of cellular immunity of patients suffering from locally advanced breast cancer with triple negative phenotype, and clinical effect of chemotherapy (cisplatin + doxorubicin/paclitaxel), and studying effects of the therapy upon subpopulation profiles of peripheral blood lymphocytes in the patients. We registered the terms of the disease progression as well as overall survival and progression-free survival. The disease progressed in 25 of 53 cases (47.2%) whereas 28 of 53 patients (52.8%) remained progression-free. The observation period was 35.5 months. Laboratory examination of the patients included immunophenotyping of peripheral blood lymphocytes and determination of NK cell cytotoxic activity before and after chemotherapy. Percentages of effectors and regulatory lymphocyte populations were determined. The results obtained showed that, for some lymphocyte subsets, the pre-treatment differences of cell percentage deviations from control were found between the progression-free groups and patients with progression of the disease. The differences in percentages of NKT cells and lymphocytes expressing CD25 activation marker proved to be most significant. Decreased number of NKT cells and activated CD25+ lymphocytes prior to chemotherapy was associated with increased probability of disease progression. Reduced percentage of NKT cells against control was observed in 56% of patients from the progression group (PD), and only 21.4% in the group free of disease progression (DF). [OR = 4.6 (95% CI 1.4 to 15.4)]. Percentage of CD25+ lymphocytes was decreased from 68.2% in the PD group, and 28.6% for DF patients [OR = 5.4 (95% CI 1.6-18.1)]. We studied relationships between the overall survival (OS) and percentage of perforin-containing NK, NKT, and T cells, and mean perforin fluorescence density (PFD) in these lymphocyte subsets in 26 of the 53 patients before treatment. A statistically significant positive correlation was revealed between OS and perforin PFD in all the three cell populations under study. Normalization of the parameters altered before treatment, and an increase of T cell numbers was observed in the disease-free patients.
Published: 2018
Full Text: View/download PDF

27. Pharmacogenetic testing of allelic variants of the CYP2D6 gene in hormone positive breast cancer

Author: L. N. Lyubchenko, M. G. Filippova, T. A. Shendrikova, L. G. Zhukova, N. I. Mekhtieva, O. V. Krokhina, and S. M. Portnoy
Subjects: tamoxifen, pharmacogenetics testing, cyp2d6 gene, hormonotherapy, breast cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Tamoxifen is the drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women in the reproductive period. The metabolic activity of tamoxifen is determined by the activity of the enzyme CYP2D6, encoded by the gene of the same name: under the action of the enzyme, tamoxifen passes into the metabolically active form, endoxyphene. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help predict the effectiveness of therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes.
Published: 2017
Full Text: View/download PDF

28. Dual plane intraoperative digital radiography in breast-conserving surgery. Maksimov N.A

Author: Maksimov, Nikita, Arslanov, Khalil, L. G. Zhukova, and Shivilov, Evgenii
Published: 2023
Full Text: View/download PDF

29. Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice

Author: D. A. Filonenko, T. M. Ibragimova, N. I. Polshina, A. V. Belogurova, E. I. Khatkova, E. A. Arutiunian, E. I. Volkova, and L. G. Zhukova
Subjects: endocrine resistance, alpelisib, pik3ca mutation, luminal breast cancer, fulvestrant, Medicine, General Medicine
Abstract: Introduction. Сombination of alpelisib plus fulvestrant is approved in patients with hormone receptor positive, HER2-negative, PIK3CA-mutated advanced breast cancer (ABC) after progression on hormonotherapy. Efficacy data of alpelisib in heavily pretreated patients with HR+/HER-2-, PIK3CA-mutated advanced breast cancer are limited, only results from phase I trial are available. Here we report our results of alpelisib efficacy in 19 heavily pretreated patients.Object: to evaluate efficacy and safety of combination alpelisib plus fulvestrant in patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer in initial and later lines of therapy in real clinical practice.Materials and methods. Combination of alpelisib plus fulvestrant was investigated in 19 patients with HR+/HER2-, PIK3CAmutated ABC, alpelisib at a dose of 300 mg per day plus fulvestrant at a dose of 500 mg i.m. every 28 days and once on day 15. Treatment continued until disease progression or unacceptable toxicity.Results. From February 2021 19 patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer were treated with alpelisib plus fulvestrant. The data cut off is October 2021. Median lines of treatment in advanced disease was five, including 19 (100%) patients received CDK4/6, 14 (74%) – fulvestrant and/or everolimus and 15 (79%) – chemotherapy. 4 (21%) received alpelisib in a second line, 15 (79%) – in subsequent lines. Median progression-free survival was 7 months. The response was evaluated in 18 patients: partial response was achieved in 5 (28%) patients, stable disease – in 9 (50%), disease progression – 4 (22%). The most frequent adverse events were hyperglycemia – 74% (grade 3 – 22%), creatinine increased – 42% and rash – 37% (grade 3 – 22%). Only one patient has discontinued the treatment due to Quincke`s edema.Conclusions. Combination of alpelisib with fulvestrant is an effective option both in initial and later lines of therapy in patients with HR+/HER2-, PIK3CA-mutated advanced breast cancer including fulvestrant, CDK4/6 inhibitors and/or everolimus – pretreated patients.
Published: 2021

30. Hereditary breast cancer: genetic and clinical hetergeneity, genetic testing, prophylactic surgery

Author: L. N. Lyubchenko, Ye. I. Bateneva, I. K. Vorotnikov, S. M. Portnoy, O. V. Krokhina, V. A. Sobolevskiy, L. G. Zhukova, V. A. Khaylenko, and S. A. Tyulyandin
Subjects: hereditary breast cancer, hereditary ovarian cancer, brca1, brca2, mutation, single nucleotide polymorphism, genetic counselling, genetic testing, prophylactic mastectomy, prophylactic oophorectomy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: 5–10 % of breast cancer cases are hereditary, 30 % of them are caused by BRCA1 and BRCA2 mutations (breast / ovarian cancer syndrome). Average cumulative risks of breast and ovarian cancer in BRCA1 mutation carriers run up to 87 % and 44 %, correspondingly. The risk for contralateral breast cancer is also high: after 25 years, 62.9 % of patients with BRCA1 mutation who were younger than 40 years of age at first breast cancer develop contralateral breast cancer. The role of single nucleotide polymorphisms in BRCA1 and BRCA2 genes modifying breast and gynaecological cancer risks is actively studied. Genetic testing is performed as a part of genetic counselling. The main inclusion criteria are multiple affected family members with breast / ovarian cancer, breast cancer at young age (under 35–50 years), ovarian cancer at any age, male breast cancer, morphological features of breast cancer (triple-negative, medullar tumors), ethnicity (Jewish ancestry). High-risk individuals carrying BRCA mutations undergo specific surveillance, chemoprophylaxis and surgery protocols. Prophylactic bilateral mastectomy reduces breast cancer risk by 90–94 %.
Published: 2015
Full Text: View/download PDF

31. Current approaches to therapy for complications of bone metastases from breast cancer

Author: L. G. Zhukova
Subjects: denosumab, complications of bone metastases, breast cancer, Gynecology and obstetrics, RG1-991
Abstract: In breast cancer, bone metastases are detectable in more than 60 % of patients. Bone metastasis-related complications (BMRCs), such as chronic pain, immobilization, and pelvic dysfunctions due to spinal cord compression, considerably worsen quality of life in patients. Intra- venous formulations of bisphosphonates (zoledronic acid, pamidronate, ibondronate, and clodronate) could reduce the risk of BMRCs by 16-40 % and increase time to the first skeletal complication up to 12–13 months. However, despite the explicit clinical efficacy of bisphospho- nates, the latter can seemingly prevent only some BMRCs. Denosumab, a fully human monoclonal antibody to RANKL, suppresses the forma- tion and functional activity of osteoclasts, thus inhibiting bone resorption.The results of a registration study have indicated that denosumab is not only as effective as zoledronic acid, but also can reduce the risk of BMRCs and significantly delay time to the first and further skeletal complications, including the need for radiotherapy, the development of hypercalcemia and pathological fractures. Denosumab is an effective, well-tolerated drug that can increase a chance of preventing BMRCs in breast cancer.
Published: 2014
Full Text: View/download PDF

32. Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Author: Inna P. Ganshina, Elena G. Ovchinnikova, Oksana M. Shalaeva, Svetlana V. Kuzmicheva, Alina N. Fedorova, Asiat I. Tekeeva, Alexander V. Sultanbaev, Elena V. Markizova, L G Zhukova, Ksenia S. Maistrenko, Svetlana A. Orlova, Irina V. Evstigneeva, Daniil L'vovich Stroyakovskiy, James J. Kolokolov, Olesya A. Kuchevskaya, Oksana N. Shirokova, Oksana I. Arapova, Elena V. Zueva, Anna V. Vasilevskaya, Tatyana A. Nersesova, Arshak A. Akopyan, Irina V. Kolyadina, Larisa Bolotina, Mariam Z. Yakubova, Sergey P. Medvedev, Alexandr S. Dergunov, Irina A. Shangina, Elvira A. Bobrova, Chulpan K. Valiakhmetova, Anna E. Storozhakova, Aleksei V. Emshanov, Natalia V. Fadeeva, Mikhail V. Volkonskiy, Yulia I. Merzlikina, Galina V. Antonova, Ivan A. Luev, Alisa R. Shumskikh, Natalia Yu. Samaneva, Elena Karabina, Natalia R. Abidova, Viktoria S. Egurenkova, Vasily V. Marfutov, Irina E. Gudkova, Lyubov Vladimirova, and Olesya A. Stativko
Subjects: Oncology, Cancer Research, medicine.medical_specialty, combined endocrine therapy with cdk4/6 inhibitors, cdk4/6, medicine.medical_treatment, Subgroup analysis, Metastasis, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, visceral metastases, Internal medicine, eribulin chemotherapy efficacy, Medicine, Adverse effect, eribulin, RC254-282, Chemotherapy, business.industry, hr+/her2- metastatic breast cancer, Cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lung metastases, medicine.disease, Metastatic breast cancer, Regimen, chemistry, eribulin chemotherapy safety, 030220 oncology & carcinogenesis, business, hormone resistance, 030215 immunology, Eribulin
Abstract: Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology. Aim. Evaluate the efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors; compare the results of the Russian study and the EMPOWER observational study in the USA. Materials and methods. The Russian observational study included 54 patients (pts) with HR+/HER2- mBC, who were treated with eribulin after CDK4/6 inhibitors in 24 Russian Cancer hospitals. The median age of pts was 56 years; 75.9% of them had recurrent BC, 24.1% de novo BC stage IV; 51.9% of pts had progression with CDK4/6 inhibitors in the first 6 months of therapy (primary endocrine resistance); 48.1% of patients had progression in the period from 6 to 38 months; 89.1% had visceral site of metastases (liver MTS 65.5%, lung MTS 52.8%, brain MTS in 7.5%). Eribulin was used after anthracyclines and taxanes in 94.4% of cases. The efficacy and safety of eribulin therapy in patients with HR+/HER2- mBC after progression with CDK4/6 inhibitors was studied, as well as subgroup analysis according to age, sites of metastasis, and previously treatment options. Results. Eribulin was prescribed in the standard regimen of 1.4 mg/m2 on days 1 and 8, the interval between cycles was 21 days, the number cyclys of chemotherapy was 144 (median 8, the mean number of cycles 10.5). With a median follow-up of 11.5 months (from 3 to 36 months), 30 patients (55.6%) continue therapy with eribulin at present; therapy was cancelled in 24 patients due to progression in 22 (40.7%) cases, and due to intolerable toxicity in 2 (3.7%) patients. The maximum response to eribulin therapy included partial response (in 11 cases, 24.4%), stable disease (in 30 cases, 66.7%) and progression in 4 (8.9%) patients. Median PFS with eribulin therapy was 10.0 months; the 6-month, 1-year, and 2-year PFS were 79.5%, 44.8% and 26.5%, respectively. Eribulin therapy was equally effective in different subgroups (p0.05) and did not depend on the age of patients, the previously received treatment, the presence of visceral MTS and liver damage. The best response to chemotherapy with eribulin was observed in lung metastases: median PFS 24 months vs 9.1 months, p=0.056. The safety profile was favorable; adverse events were registered in 34.5% of patients, which required dose adjustment in 18.5% of cases. With a median follow-up of 11.5 months, 92.6% of patients remain alive. Conclusion. Eribulin has demonstrated high efficacy and favorable safety profile in hormone-resistant HER2- mBC in patients with progression when receiving CDK4/6 inhibitor.
Published: 2021

33. Abstract PS10-05: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial

Author: J. Wu, Constanta Timcheva, L. Menon-Singh, Miguel Martín, Katie Zhou, Guy Jerusalem, Michelino De Laurentiis, Claudio Zamagni, L G Zhukova, Janice Lu, Aleix Prat, Senthil Rajappa, Paul Cottu, and Stephen Chia
Subjects: Cancer Research, medicine.medical_specialty, education.field_of_study, business.industry, Letrozole, Population, Goserelin, Neutropenia, medicine.disease, Gastroenterology, Discontinuation, Breast cancer, Oncology, Tolerability, Internal medicine, medicine, business, education, Progressive disease, medicine.drug
Abstract: Background: CompLEEment-1 (NCT02941926) is an ongoing Phase IIIb trial of ribociclib (RIB) in combination with letrozole (LET) in the first-line setting for patients (pts) with HR+, HER2- ABC, reflecting a real-world clinical setting by including a more diverse pt population than those included in the pivotal MONALEESA trials. Here we report further analyses of the primary endpoint of safety from the completed Core Phase of the trial. Methods: CompLEEment-1 included women of any menopausal status and men with HR+, HER2- ABC treated with ≤1 line of prior chemotherapy and no prior hormonal therapy for advanced disease. Pts received RIB (600 mg QD, 3 weeks on/1 week off) in combination with LET (2.5 mg QD, continuous). Premenopausal women and men received a luteinizing hormone-releasing hormone agonist (3.6 mg goserelin or 7.5 mg leuprolide, Q28D). The primary endpoints were safety and tolerability. Updated analyses included dose reduction/interruption or treatment discontinuation due to adverse events (AEs), clinical impact of AEs of special interest (AESI), and exposure-adjusted incidence/occurrence rates (IRs) for AESI. Results: At data cutoff (November 8, 2019) 3,246 pts had been evaluated (median follow-up of 25.4 months), and median duration of exposure to RIB was 17.5 months; 1,301 (40.1%) pts completed Core Phase treatment, 415 of whom moved to the Extension Phase. Overall, 1,945 (59.9%) pts permanently discontinued treatment, mostly due to progressive disease (34.2%) and AEs (15.5%). Treatment-related AEs were reported in 3,091 (95.2%) pts, leading to dose modification in 2,235 (68.9%) pts. Dose modification occurred most often in pts with grade ≥3 neutropenia (dose interruption, 1,671 [51.5%] pts; dose reduction, 480 [14.8%] pts); treatment discontinuation occurred most frequently in pts with grade ≥3 increased alanine aminotransferase (ALT; 116 [3.6%] pts) or aspartate aminotransferase (AST; 68 [2.1%] pts). Grade ≥3 neutropenia occurred in 1,856 (57.2%) pts, with the median time to first occurrence of 4.1 weeks and median duration of first occurrence of 1.1 weeks. As measured by laboratory values, grade ≥2 increased ALT and AST occurred in 453 (14.0%) and 380 (11.7%) pts, respectively. Grade ≥2 QTcF prolongation was infrequent, occurring in 101 (3.1%) pts, leading 8 (0.2%) pts to discontinue from treatment. AESI rarely led to hospitalization (0 to 0.3%) and none were fatal. Exposure-adjusted IRs for AESI per 100 patient-years of exposure show that with increasing RIB exposure, the IR and the event rates for AESI decreased by a factor of ×2 to ×8 from 0-1 years compared with 1-2 years (Table 1). Conclusions: AEs associated with RIB + LET combination therapy were manageable, consistent with previous Phase III trials of RIB + LET - and adjusted IRs for AESI notably decreased from Year 1 to Year 2 of treatment. These data further support the use of RIB + LET for first-line treatment of HR+, HER2- ABC in both men and women of any menopausal status and in a broader and more diverse patient population. Table 1. Exposure-adjusted IRs for selected AESI per 100 patient-years of exposure0-1 years1-2 yearsAESIIR per 100 PTYaEvents per 100 PTYbIR per 100 PTYaEvents per 100 PTYbNeutropenia276.76410.2292.43200.83ALT increased20.3741.663.796.32AST increased17.5133.272.944.61QTcF prolongation8.4410.221.081.26aIR per 100 PTY: n/100 PTY, number of patients with an event divided by the corresponding sum of the exposure duration for patients, where duration of exposure in patient treatment-years (PTY) is counted up to the first qualifying event (or duration of exposure in time interval for patients without an event).bEvents per 100 PTY: n/100 PTY, number of events divided by the corresponding sum of the exposure duration, where duration of exposure in patient treatment-years (PTY) is duration of exposure in time interval. Citation Format: Janice Lu, Paul Cottu, Miguel Martín, Claudio Zamagni, Aleix Prat, Stephen Chia, Guy Jerusalem, Senthil Rajappa, Constanta Timcheva, Lyudmila Zhukova, Katie Zhou, Jiwen Wu, Lakshmi Menon-Singh, Michelino De Laurentiis. Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Expanded safety analysis of the phase IIIb CompLEEment-1 trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-05.
Published: 2021

34. Renal service during the COVID-19 pandemic (Association of nephrologists position statement)

Author: L. G. Zhukova, Irina Bobkova, А. B. Zulkarnaev, D. V. Politov, Vladimir Dobronravov, V. N. Stepanov, S Sh Butrimova, E. V. Tkachenko, Alexei Smirnov, A. A. Shumilina, E. V. Antonova, M. V. Bush, A. V. Vatazin, and M. M. Batiushin
Subjects: Position statement, Nephrology, Service (business), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Context (language use), Quality of life (healthcare), Internal medicine, Health care, Emergency medicine, Pandemic, Medicine, business
Abstract: The editorial touches upon the problem of the possible impact of COVID-19 on CKD patients, mediated by the forced reorganization of the health care system in a whole, the redistribution of its resources in the context of the COVID-19 pandemic. Lack of regular outpatient monitoring, delayed diagnosis and therapy in patients with kidney dysfunction are factors of adverse clinical outcomes - accelerated disease progression, ESKD development and the need for KRT, life-threatening complications, reduced quality of life and survival. The data of a pooled analysis of the impact of the pandemic on specialized renal care and its availability in a number of regions of the Northwest Federal District of Russia and the Moscow Region are presented: a fall in hospital admissions, outpatient consultations and a decrease in the use of hospital beds (on average, by 37 %, 40 % and 32 %, respectively). Principles and conditions of the functioning of health systems associated in the COVID-19 pandemic have been discussed. The main approaches to maintaining the standard level of renal patients care have been formulated, aimed at preventing an unfavorable patient-oriented CKD outcomes. © 2021 Patristica et Mediaevalia. All rights reserved.
Published: 2021

35. Resolution on the results of scientific-practical conference 'Clinical evidence of increasing overall survival in the treatment of metastatic breast cancer', held on 29 November 2014 under the auspices of the Department of health of Moscow

Author: E. T. Bairamov, A. V. Belonogov, V. V. Brusnichkina, A. V. Bulakh, M. Y. Byahov, S. N. Gurov, G. G. Eremeev, N. V. Zhukov, L. G. Zhukova, L. M. Kogonia, P. V. Koposov, L. K. Ovchinnikova, V. V. Radlevich, E. A. Samyshina, A. P. Seryakov, M. D. Ter-Ovanesov, and I. E. Shumskaya
Subjects: Medicine
Abstract: Objectives: discussion of modern treatment options for metastatic breast cancer (MBC), the determining of the optimal treatment for subgroups of patients with poor prognosis.
Published: 2015

36. Olaparib in the metastatic HER2-negative breast cancer setting

Author: E. V. Lubennikova, L G Zhukova, E. I. Khatkova, Inna P. Ganshina, and Irina V. Kolyadina
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, parp-inhibitor, lucy, olaparib, Olaparib, 03 medical and health sciences, chemistry.chemical_compound, breast cancer, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, business.industry, HER2 negative, General Medicine, medicine.disease, 030104 developmental biology, chemistry, olympiad, 030220 oncology & carcinogenesis, brca, Medicine, business
Abstract: Understanding of cancer biology is at the cornerstone of design of new and effective treatment strategies. Identification of molecular drivers of tumor growth and progression allow identify right patient for the right treatment for personalized treatment plan optimization. Breast cancer (BC) encompasses a heterogeneous collection of neoplasms with diverse morphologies, molecular phenotypes, responses to therapy, probabilities of relapse and overall survival. Molecular and histopathological classification aims to categories tumors into subgroups to inform clinical decisions, to improve long-term treatment results and maintain the quality of life of this group of patients. Germinal mutation in the BRCA1/2 (BRCAm) genes in a tumor determines the hereditary predisposition, disease manifestation, therapeutic options and clinical efficacy. Therefore, patients withBRCAmBCrepresent a special subgroup requiring personalized treatment approach.Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is a targeted therapeutic agent that acts as inhibitor of single-strand breaks reparation, leading to their accumulation, conversion to double-strand breaks and eventually to cancer cell apoptosis. Olaparib is a first-in-class PARP-inhibitor with an outstanding antineoplastic activity known for some malignant tumors, demonstrates effectiveness and safety of therapy inBRCAmBCas well. The results of OlympiAD and LUCY trials are represented in the article. Subgroup analysis may define the patient population that would benefit from PARP inhibitors therapy.
Published: 2020

37. Abstract P2-16-34: Patterns of survival and efficacy of chemotherapy in elderly patients with triple-negative breast cancer treated in the neoadjuvant setting

Author: L G Zhukova, Irina V. Kolyadina, Olga O. Gordeeva, Inna P. Ganshina, Andrey Meshcheryakov, and Dmitry Komov
Subjects: Cisplatin, Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Breast surgery, Cancer, medicine.disease, Breast cancer, Internal medicine, medicine, Stage (cooking), business, Neoadjuvant therapy, Triple-negative breast cancer, medicine.drug
Abstract: Background. Triple negative breast cancer (TNBC) is the most aggressive molecular subtype. It is mostly observed in younger patients, however, substantial proportion of patients are above age of 60. Despite that, this group of patients was not studied and analyzed separately in previous studies. Objectives. To establish efficacy of neoadjuvant chemotherapy in elderly patients with stage II-III TNBC and patterns of progression for this group of patients. Methods. Since 2014 we treated 92 patients with histologically confirmed stage II-III TNBC. Neoadjuvant therapy included 6 cycles of Cisplatin 75mg/m2 day 1 and Paclitaxel 80mg/m2 days 1, 8, 15, every 4 weeks according to local protocol. After neoadjuvant chemotherapy patients proceeded to radical breast surgery with assessing pathological response. Then we analyzed clinical characteristics of patients and their survival according to the pathological response achieved. Results. In our analysis were included 92 patients, 22 of them were elderly patients (above 60). Pathological complete response was achieved in 57,6% of all patients. In the elderly group we observed significantly higher proportion of tumors with advanced stages (N3: 40,9% vs 20,0%, p Table 1. Survival outcomes.SurvivalBelow 60 y.o.Above 60 y.o.Recurrence-free survival Conclusion. In our analysis elderly patients with early and locally advanced TNBC demonstrate decreased response, another safety profile and lower survival rates. Different efficacy could be explained with lower number of cycles of neoadjuvant chemotherapy administered and more advanced stages upon presentation. Different metastatic patterns which we observed in younger and elderly patients should be further studied. Citation Format: Olga Gordeeva, Irina Kolyadina, Lyudmila Zhukova, Inna Ganshina, Dmitry Komov, Andrey Meshcheryakov. Patterns of survival and efficacy of chemotherapy in elderly patients with triple-negative breast cancer treated in the neoadjuvant setting [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-16-34.
Published: 2020

38. Postneoadjuvant therapy: a new approach to the treatment of HER2-positive breast cancer (KATHERINE study results)

Author: L. G. Zhukova and S. A. Smolin
Subjects: Oncology, medicine.medical_specialty, Tumour regression, medicine.medical_treatment, katherine, chemistry.chemical_compound, Breast cancer, breast cancer, Trastuzumab, Internal medicine, her2-positive breast cancer, medicine, Adjuvant therapy, skin and connective tissue diseases, residual tumor, Neoadjuvant therapy, trastuzumab emtansine, t-dm1, business.industry, adjuvant therapy, General Medicine, medicine.disease, Interim analysis, idfs, chemistry, Trastuzumab emtansine, Medicine, business, Adjuvant, medicine.drug
Abstract: Up until recently, neoadjuvant and adjuvant treatment regimens for breast cancer (BC) were considered equivalent in their effect on long-term treatment outcomes. Despite the fact that additional information on the prognosis of patients (achievement or failure to achieve complete drug pathomorphosis) was obtained during neoadjuvant therapy, we could not change this prognosis, since there was no evidence that any variant of adjuvant therapy could improve survival of patients, who did not achieve complete morphological tumour regression. In December 2018, investigators presented the results of the first planned interim analysis of invasive disease-free survival (iDFS) of patients with early HER2-positive breast cancer, who had residual tumour after neoadjuvant anti-HER2-containing therapy, depending on the adjuvant treatment option: either trastuzumab emtansine (n = 743) or trastuzumab (n = 743). The expected 3-year iDFS in patients, who received trastuzumab emtansine as adjuvant therapy, was 88.3%, while that in the standard trastuzumab group accounted for only 77% (RR = 0.50; 95% CI 0.39–0, 64; h
Published: 2019

39. The role of systemic therapy in localized pancreatic cancer (review)

Author: B. I. Bammatov, K. S. Grechukhina, S. A. Smolin, and L. G. Zhukova
Subjects: Resectable Pancreatic Cancer, Oncology, medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Gastroenterology, Cancer, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Borderline resectable, Surgical oncology, 030220 oncology & carcinogenesis, Pancreatic cancer, Internal medicine, medicine, Adjuvant therapy, Surgery, 030212 general & internal medicine, Pancreas, business, Neoadjuvant therapy
Abstract: The results of treatment of localized (early) pancreatic cancer are unsatisfactory despite all achievements of modern clinical and surgical oncology. Nevertheless, certain success was achieved even in these extremely unfavorable patients regarding their prognosis. The authors analyzed evolution of adjuvant therapy, as well as new concepts in the treatment of borderline resectable and resectable pancreatic cancer. Modern anticancer therapy with acceptable toxicity profile significantly improved the outcomes. However, further research is needed to improve the effectiveness of treatment despite favorable current results.
Published: 2019

40. Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Author: L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, K. S. Grechukhina, S. A. Smolin, E. A. Arutyunyan, and E. M. Kolyago
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, palbociclib, business.industry, General Medicine, Palbociclib, endocrinotherapy, medicine.disease, Clinical Practice, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, breast cancer, 030220 oncology & carcinogenesis, Internal medicine, medicine, Medicine, business, skin and connective tissue diseases, neoplasms
Abstract: Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast cancer (mBC). Palbociclib has gained world attention and is included in all clinical guidelines, both international and domestic, as a new standard of first- and second-line therapy of HRP+ HER2- mBC. The article presents the updated results of PALOMA-2 and PALOMA-3 studies and the results of use of palbociclib in combination with ET in real clinical practice.
Published: 2019

41. BJS commission on surgery and perioperative care post-COVID-19

Author: E. Abahuje, A. Abbas, M. Abd El Aziz Abd El Maksoud, A. Abdelhady, S. Abdelhamid, H. Abdelkarem Ahmed Faraj, B. Abdelqader, T. Abdelrahman, H. Abdou, A. Abdullah, M. Abedua Harrison, E. Abem Owusu, A. Aboalazayem, R. Aboulhosn, S. Abu Oda, A. Abubakar, A. Abutaka, D. Acevedo Fontalvo, S. Acuna, A. Adefemi, S. Adegbola, T. Adenuga, A. Adeyeye, A. Adil Hilmi, A. Adisa, K. Aditya, T. Adjeso, R. Aftab, A. Afzal, V. Aggarwal, A. Aggarwal, R. Aguilera, M. -L. Aguilera-Are´valo, E. J. Aguirre Salamanca, I. Aguirre-Allende, D. Ahari, H. Ahmad, F. Ahmad Rauf, A. Ahmad Zartasht Khan, S. Ahmed, N. Ahmed Fieturi, S. Ahmed Mohamed, Z. Ahmed-Bakhsh, M. Ahsan Javed, L. Akano, A. Akbar, M. Akhbari, P. Akhmedov, G. Aksit, Y. Akula, A. S. Alagaratnam, S. Al Majid, O. Al Mukhtar, H. Al Omran, N. AlAsali, M. Al-Azzawi, R. Al-Habsi, H. Al-Iraqi, H. Al-Naggar, E. Alameer, H. Albirnawi, D. Alderson, F. Aldulaijan, R. Alejandro Miranda Ojeda, A. AlHasan, S. Ali, A. Ali, M. Ali Khan, Y. Alimova, F. Aljanadi, R. Aljubure, N. Allopi, H. Almedbal, M. Almubarak, Z. Alqaidoom, N. Alselaim, M. Alshaar, R. Alshammari, K. Altaf, S. Altıner, B. Altunpak, L. A. Alvarez Lozada, E. Amal Nahal, A. Amer, K. Amin, U. Aminu, N. Amisi Numbi, T. Amjad, R. Amoah, Y. An, N. -A. Anastasopoulos, J. Andre´s Urrutia, F. Angarita, K. -L. Angarita, M. A´ ngel FreirI´a Eiras, A. Antypas, M. A. Anwar, H. Anwar, T. O. Apampa, K. Apostolou, C. Aquina, R. Arachchige Adithi Himika Randeni, M. I. Archila Godı´nez, O. Arez, A. A. Arezzo, P. Armonis, S. Arshad, M. Arshad Salman, A. Arshid, P. C. Arteaga Asensio, T. Arthur, A. Arumuga Jothi, F. Aryo Damara, L. Asensio Gomez, J. Ashcroft, S. Ashraf, A. Asif, M. Atif, M. Attaullah Khan, N. Avellaneda, S. Awad, M. Awadh, A. Axiaq, A. Ayad Mohammed Shuwayyah, D. Ayalew, E. Aytac, F. Azam, J. Azevedo, B. Azhar, J. Aziz, A. Aziz, A. Azzam, A. Baba Ndajiwo, M. Baig, D. Baker, F. Bakko, R. Balachandran, G. Balachandran, J. Balagizi Mudekereza, E. Balai, B. Balci, A. Balduzzi, A. Balhareth, S. Bandyopadhyay, D. Banerjee, D. Bangalore Mahalinga, B. Bankhead-Kendall, N. D. A. Bankole, V. Banwell, F. Baris Bengur, B. Baris Ozmen, M. Barnard, R. Barnett, J. A. Barreras Espinoza, A. Barrios, G. Bass, M. Bass, A. Bausys, A. Bavikatte, J. Bayram, M. Belousov, A. G. Berardi, A. Beamish, C. Beattie, F. Belia, V. Bellato, S. Bellikatti, S. Benjamens, C. Benlice, S. Bennedsgaard, S. Bennett, Z. Bentounsi, H. Bergenfeldt, A. Bergenfelz, M. Besselink, G. Bhandoria, E. Bhangu, M. Bhatia, M. T. Bhatti, Z. Bilgili, G. Bislenghi, C. Bisset, S. Biswas, J. Blake, R. Blanco, L. Boccalatte, R. Boden, C. Bojanic, M. Boland, P. Boland, E. Bollen, E. -A. Bonci, L. Boni, A. Booth, R. Booth, A. Borakati, G. E. Borunda Escudero, S. J. Bosco, P. Bostro¨ m, P. Botelho de Alencar Ferreira Cruz, K. Bouchagier, A. Bouhuwaish, M. Boutros, K. Boyce, C. Boyle, L. Bradshaw, A. Brandl, A. Brar, G. Brat, H. Brenkman, C. Brennan, C. Brines, A. Brookmyre, C. Brosnan, L. Brouwers, A. Brown, L. Brown, C. Brown, J. Brown, V. BS, M. Buksh, M. Bunani Emmanuel, D. Burbano, A. Burelli, A. Burke, J. Burke, N. Burlov, A. Burns, O. Burton, A. Butt, B. Buzra Ozkan, L. Cabrera Silva, E. Y. Caicedo, T. Calderbank, W. Cambridge, G. Campelo, O. Can Tatar, F. Carbone, F. Carrano, D. Casallas, D. Casanova Portoles, F. Casciani, I. Cassimjee, O. A. Castaneda Ramı´rez, V. Catala´ n, J. Caviedes, L. Cayetano, M. ~ Ceresoli, M. Chan, V. Chan, P. Chandrasinghe, S. Chapman, A. Chaturvedi, D. Chaudhry, H. Chaudry, H. W. Chen, A. Cheng, M. Chernykh, A. M. Cherrie, I. Cheruiyot, J. Cheung, C. Chia, J. Chica, N. Chinai, A. Chirwa, J. Chiwaligo, A. Choi, J. Choi, M. R. Chowdhury, E. Christopher, N. Christou, T. Chu, D. Chua, H. W. Chua, C. Chung, A. Cihat Yildirim, M. Cillo, S. Cioffi, H. Claireaux, S. Clermonts, R. Clifford, M. Climent, A. Clynch, R. -J. Coelen, E. Cola´ s-Ruiz, A. Collar, M. Collard, K. C. Conlon, T. Connelly, K. Connor, J. A. Cook, T. Correia de Sa´, N. Cos¸gun Acar, T. Costa, D. Couch, S. Cowper, B. Creavin, B. Crook, A. Curell, R. D’alessio, J. Dale, J. Damgaard Eriksen, I. Dario Martin Gonzalez, A. Darwish, M. Das, R. Das, K. Das, R. Dave, S. O. David, T. Davies, C. Davis, S. Davison, V. Davletshina, A. Dawidziuk, A. Dawson, M. de Andres Crespo, H. de Berker, P. de Dieu Ngo, E. Dekker, R. de la Caridad Espinosa Luis, B. de Lacy, N. Demartines, A. de Montserrat Medina Sifuentes, S. De Silva, C. del Rio, V. Delaune, A. Dell, I. Demirbas¸, S. Demirli Atici, M. Deniz Tepe, M. Derebey, G. Desai, M. Desai, S. Devarakonda, N. Deveras, G. Di Franco, M. Di Martino, F. Di Marzo, A´ . Dı´az, G. Diaz del Gobbo, C. DiazCastrillon, L. Dick, K. Dickinson, E. Diego, I. Dimasi, A. Ding, S. Dingemans, L. Dixon, B. Dixon, W. Doherty, D. Dooreemeah, C. Donohue, M. Dornseifer, F. Dossa, W. Dossou, T. Drake, I. Drami, G. Drevin, M. C. du Plessis, N. Dudi-Venkata, R. Dudley, S. Duffy, D. Duklas, B. -D. Dumbrava, F. Duygu Avlar, A. Dworzynska, W. Ebrahim, A. Ebrahim, E. Efre´n Lozada Herna´ ndez, N. Ehigie, M. El Boghdady, C. El Hasnaoui, M. El Sheikh, A. El-Hussuna, O. Eldurssi, H. Elfeki, M. Elhadi, M. Elhassan, A. Elhissi, B. Elliot, C. Elsenbroek, B. Elsolh, N. Elson, H. Eltyeb, H. Emerson, S. H. Emile, G. Endalle, W. English, C. Ercisli, G. Espinosa, M. Essam Abdelraheem, H. Essangri, P. Etienne, M. D. Evans, T. Evans, C. Ezeme, F. Ezzahraa, T. Fadalla, J. Fagan, M. Fahmy, C. Fairfield, O. Falade, S. Famularo, F. Faqar-Uz-Zaman, Y. Farid, A. Farooq, H. Farooq, F. Farooqui, B. Farquharson, A. Faruqi, R. Faulder, M. Faut, K. Fechner, T. Feenstra, M. Fehervari, L. Fernandez, J. Ferna´ ndez Alberti, L. Ferrario, D. Field, L. Fiore, S. Fingerhut, S. Finlayson, N. Fleming, C. Fleming, E. Florial, M. Fok, D. Fokin, M. Foley, M. P. Forero, T. Forgan, M. Fornasiero, H. Fowler, G. Fowler, E. Franchi, L. Franklin, A˚ . Fredriksson, P. Fruhling, G. Fuentes Navarrette, A. Fu¨ lo¨ p, M. Furtado, T. Gaarder, N. Galbraith, I. T. K. Gallagher, G. Gallo, T. Gana, E. Gaskin, M. Gasparini, R. G. Gatan, E. Geary, K. Gelaye Wudineh, G. Gemenetzis, M. Georgi, H. Ghalige, W. Ghareeb, T. Ghatwary Tantawy, C. Ghomsi, A. Ghuman, P. Giannakis, F. Giron, K. Gjengedal, E. Gkotsis, J. Glasbey, S. Godahewa, D. Godula, P. Goffredo, S. Goh, M. Golriz, L. Gomez, D. Gomez Gomez, R. Gonzalez, D. Gonzalez, E. Gonzalez Gutierrez, D. Gopar, L. Gordini, A. Gori, S. Gorta´ zar, N. Gousy, R. Gowda, M. Gowda, J. Gqada, M. Grechenig, J. Greer, L. Grego´ rio, A. Grigorova, H. Grimes, V. Groot, R. C. Grossman, R. Gruber, A. Gru¨ ter, R. Guest, R. Gujjuri, E. Gu¨ lc¸ek, B. Gulcu, K. Gull, M. Gulmez, V. Gupta, A. Gutlic, T. Guven, T. Gwatirisa, G. Gwini, P. Gwodog, S. Gysling, M. Habib, A. B. Hafeez Bhatti, J. Hallesmith, S. Halloran, M. Hamza Sadiq, C. Haney, N. Hanna, L. Hanna, M. Hannington, J. Harbjerg, D. Haribaskaran, N. Harran, B. Harrington, E. Harrison, R. Hasan, S. Hashmi, M. Hassan, A. Hassan, L. Haverkamp, S. Hazen, B. Heer, J. Heil, J. Helliwell, N. Henriksen, D. Henshall, M. Hermanson, S. Hermena, D. Hettiarachchi, C. Hextall, M. Hidalgo, H. Hidayat, A. Hider, P. Higgins, R. Hinchliffe, D. Hirani, D. Hirpara, I. Hisham, M. Hite, S. M. Hoh, C. Holmberg, E. Ho¨ lmich, F. Holst, A. Hossam, A. Hossam Elfallal, P. Howard, E. Huaman, Y. Huang, L. Huang, D. Huang, T. Huber, J. Hugh, J. Hughes, F. Hu¨ ttner, R. Huynh, A. Hylands, J. Iannuzzi, B. Ielpo, A. Iftikhar Talib, J. Ignacio, P. Ignatavicius, S. Ike, C. Ikwu, M. Inama, A. Ing, A. Ingels, A. Isik, N. Islam, I. J. Ives, A. J. M. S. AlHasan, C. J. Perez Rivera, F. Ja´ come, T. Jaffer, O. Jagiella-Lodise, M. Jain, K. Jain, M. Jakubauskas, M. Jalal, H. James, Y. Jang, B. Janssen, H. Jansson, U´ . Jariod-Ferrer, H. Javanmard, S. Javed, U. Jayarajah, I. Jayasuriya, J. Je, Z. Jessop, E. Jia Lin Tang, H. Jiang, Y. Jiayan, T. Jih Huei, R. Jimenez-Rodriguez, D. Joh, A. Johnson, N. Jones, C. Jones, C. Jordan, J. Jose´ Nu´ nez Ju, ~ M. Jose´ Pizarro, C. Jose Salazar J. Joseph, C. Justiniano, T. Kabir, M. Kadhum, C. Kalfountzos, E. Kalogiannaki, K. Kalyanasundaram, S. Kamarajah, M. Kamil Quraishi, Y. Kanemitsu, A. Kapila, V. Kapila, G. Karagiannidis, M. Kashif, S. Kathiravelupillai, A. Kathiravelupillai, E. Katsogridakis, K. Kaur, H. Kaur Sekhon Inderjit Singh, N. Kausur, M. Kawka, G. Keehan, S. Kehlet Watt, M. Kelly, M. E. Kelly, I. Kelvin Egbuchulem, G. Kembuan, E. Khajeh, A. Khaled Elfaitur, M. F. Khan, S. Khan, M. Khan, D. Khan, H. Khan, H. Khatkar, E. Khatkov, R. Khaw, B. Kim, K. Kishore Siddiraju, D. Kitua, B. Kırımtay, S. Kmezic, S. Knight, T. Koe¨ter, A. Koh, F. Koh Hong Xiang, T. Kojo Anyomih, A. I. N. Kok, R. Kokelaar, I. Koliarakis, S. Kolli, J. Kong, D. Ko¨ nig, M. otze, A. Kourdouli, M. Kowal, A. Kraima, F. Kramer, M. Kryzauskas, I. Kuchynskyi, C. Kuemmerli, S. Kuiper, S. Kumar, A. Kumar, L. Kumar, H. Kumar, N. Kumar, S. Kumar Bandyopadhyay, P. Kumar Garg, S. Kumar Venkatappa, J. Kung, S. Kural, A. Kushairi, E. Kuuzie, M. Kvietkauskas, I. Kwek, J. La, L. Lai, S. Lakpriya, K. Lam, M. Lami, I. Lansdorp-Vogelaar, P. Lapolla, H. Larsen, J. Latif, U. Laudari, A. Laurnezi, A. Lawal, S. Lawday, H. Lederhuber, A. Lednev, R. Lee, M. E. van Leerdam, G. Lefevbre, M. Lesmus, F. A. Leyva Moraga, E. Leyva Moraga, F. Leyva Moraga, H. L. Li, A. Li, Z. Li, E. Licardie, A. Light, A. L. Lightner, A. Lin, E. Lincango, F. Litta, H. Liu, B. Lofthouse, M. A. Londono, R. Lopes, R. Lopes de Freitas, L. Lopez, A. I. Lo´ pez, J. ~ Lopez-Gomez, G. Lopez-Pena, R. Lowe, D. Lowe, M. Lowey, G. Loy, V. Lozanovski, J. Luzon, P. Lynn, T. Maccabe, A. Machielsen, C. A. Mafla Herrerı´a, L. Maggino, K. Mahawar, D. Mahmood, M. Mahmoud, K. Mahtani, I. Maitra, S. Maji, I. Majiet, L. Mal, J. Malherbe, K. Malhotra, P. Malkomes, E. Man, A. Manan Sheikh, S. Manjunath, R. Manzano Nunez, S. Manzoor, R. Maqsood, G. ~ Marchegiani, F. Marchegiani, D. Marı´n, A. Marin, I. Marks, E. Marson, A. Martensen, D. Martin, G. Martı´n Martı´n, B. Martin-Perez, P. Martinez, P. Marwaha, C. Mashauri, H. Mashbari, Ł. Masior, R. Masri, L. Masud, S. Masudi, G. Mateu Calabuig, S. Math, A. Matrachisia, J. Mayol, D. Mazingi, A. Mazzotta, J. McAlinden, G. McCabe, L. McColm, H. McElvaney, K. McGivern, J. McGovern, E. McGuinness, N. McInerney, S. Mckay, C. McKee, M. McKenna, N. McKenna, K. McLean, S. Mediratta, Y. Medkova, O. Medzhidov, A. Mehraj, M. Mekhael, O. Mekinde, C. Mellenthin, A. Melucci, K. Mentor, J. Merchant, H. Messias, M. Messeha, C. Meza, P. Mhango, M. Miladinov, M. Milagros Niquen Jimenez, P. Miller, E. Mills, A. Milton, O. A. Minayeva, Z. MinHua Zheng, H. Mischlinger, B. Mo¨ ckli, R. Modi, H. M. Mohamed, M. Mohamed, T. Mohamed Abulghasm, S. A. Mohammad, T. O. Mohammed, A. Mohammed, H. Mohan, M. Mohan, I. Moin, V. Mok, G. Molina, J. Moloney, J. Moneim, M. Monfort Mira, B. Montcusı´ Ventura, M. Montouri, M. Moossdorff, I. Mora-Guzma´ n, B. Moran, R. A. R. Mora´ n, S. Moreno-Ordaz, A´ . Morera, R. Morgan, R. Morley, D. Moro-Valdezate, S. Moros, J. -L. Moss, A. Morven, D. Morton, A. Moynihan, M. Moyo´ n, N. Muduli, N. Mugla, W. Mugla, P. Mu¨ ller, G. Mun, R. Mundhada, I. Munir, F. Munoz, E. Mu ~ noz, A. Mu ~ noz, D. ~ C. Munoz Balderas, E. Murgitroyd, V. Murray, S. Murthy, W. ~ Mushiwokufa, H. Mustafa, B. Mustakimov, P. Mutambanengwe, P. Myint, S. Nadkarni, P. A. Naess, S. Nahar, P. Naidoo, R. Nam, S. Nandhra, N. Nanjappa, V. Narasimhan, W. Nardi, M. Nasir, A. Naughton, D. Naumann, S. Navarro, M. Nawaaz Karimbocus, A. Nazir, S. Ndereya, A. Ndong, I. Negoi, D. Nel, D. Nelson, S. Nepal, T. Nugent, D. Nepogodiev, J. Neufeld, J. Ng, D. Ng, C. E. Ng, S. Ngaserin, L. Ngu, E. Ngwenya, R. N. Fhearaigh, T. -K. Nikolousakis, M. Ninkovic, G. Nita, C. Nitschke, E. Noren, T. Noton, A. Novikova, Z. Nowinka, T. Nyakunengwa, A. Nyalundja, I. Nzenwa, H. Ø Kristensen, C. O’Brien, L. O’Brien, S. O’Brien, J. O’Reilly, S. O’Rourke, M. O’Sullivan, M. O’Dwyer, L. Ochieng, E. Oderoha, K. E. Oh, L. O¨ hlberger, M. O¨ lc¸u¨ m, A. Olkina, M. Omkumar, B. Omnitel, D. Oncel Yakar, K. Ong, L. Ong Wei Lin, R. Ooi, S. Ooi, A. Oomman, D. Oon Tyjet, S. Opiyo, J. J. Oscullo Yepez, N. Osei-kuffour, T. Osunronbi, A. Ottlaka´ n, S. Oussama Kacimi, S. Ovaere, A. Ozair, F. Pachler, S. Pai Oo, S. Paiella, L. Panaiotti, N. Panda, S. Pandarinath, D. Pandey, S. Pandrowala, F. Papa Mamadou, M. Paranathala, J. Park, C. Parmar, A. Parvez, L. Pasovic, A. Pasquer, N. Pasumarthy, F. Pata, T. Patel, P. Patel, N. Patel, M. Patel, N. Patron Uriburu, R. Patrone, A. Paul, O. M. Pavan Kumar, A. Pavithran, M. Pedraza Ciro, G. Pellino, A. Peloso, M. T. Pena~ Gallardo, A. Pena Velazquez, J. Perea, L. E. Pe´rez-Sa´ nchez, T. ~ Perra, G. Perrotta, P. Petersson, G. Petra, N. Petrucciani, C. Pickin, V. Pino, E. Pinotti, F. Pinto, P. Plum, F. Podesta, T. Pollini, M. Pompeu Sa´, F. Ponce Leon, H. S. Ponniah, X. Ponte de Sousa, J. Ponton, A. Pontula, M. Popa, A. L. Portilla, F. Posner, S. Post, A. Potolicchio, S. Pouwels, A. Povo, P. Prasad, S. Preciado, R. Preece, D. Proud, J. A. Pulido Segura, N. Puliyath, M. Qui, A. S. Quimbaya Rodrı´guez, W. Raby-Smith, A. Racovit¸a, A. Rad, R. Radwan, M. Rafaih Iqbal, A. Rafik, B. Raguan, M. Rahi, J. -L. Rahiri, J. Rahme, L. Rai, A. Raj, A. Raj Saksena, M. Raja, J. Ramirez, J. Ramzi, J. Ranstam, C. Rao, A. Rashid, B. Ratnayake, K. Rattanasirivilai, K. Raubenheimer, N. Ravikumar, S. Ravn, N. Razoz, W. Rea, A. Regan, M. Rela, A. Remme, C. E. Rey Chaves, A. Reyes, A. Riad, D. Rice, K. Rios Quintana, A. Ritter, M. Roalsø, D. Robinson, J. Rodriguez, F. Rodrı´guez, M. C. Rodriguez, A. Rogers, J. Rohila, D. Romanyuc, I. Romic, M. Rommaneh, G. Rompianesi, F. Rosa, F. Roscio, A. Rose, T. Rotimi, H. Ruiz, J. Ruiz Yucuma, E. Ruiz-U´ car, M. Ruslan, M. Rutega˚ rd, E. Ryan Harper, A. Ryckx, D. Rydbeck, E. Fonseca, A. Sanchez Teran, S. Sanchez Ussa, O. Sandli, H. Sanfey, J. Sanghera, I. Sani, M. Santafe Guerrero, M. Sante Fornasiero, O. Santes Jasso, I. Santos Pereira, H. Santos Sousa, A. Saratzis, A. Sarmiento Alarcon, T. Saumtally, R. Sayyed, M. Schettino, L. Schleimer, T. Schmidt, K. Schondffelt, M. Schwab, A. Scott, H. Searle, L. Sebopelo, B. Seeglier, R. Seishima, D. Semenvov, A. Senent-Boza, J. Sepulveda, M. Serenari, M. Serrano Navidad, I. Sert, E. Sewart, A. Sgro`, V. Shadrina, K. Shah, F. Shahid, M. Shalaby, B. Shankar, J. Shapiro, L. Sharma, A. Sheel, A. Shenfine, S. Shenoy, A. Sherif, N. Shetty, R. Shetty, T. C. Sia, D. Sichimba, H. Siddique, I. Siddiqui, G. Simkens, J. Simoe, H. Simon, L. Sinan, T. Singh, K. Singh, Y. Singh, L. Sinha, L. Siragusa, T. Sluckin, Y. W. Smart, H. Smith, K. Smith, L. Smits, C. Sneep-van Kessel, C. Sohrabi, O. Solo´ rzano Pineda, A. Soma, L. Sooriyapiragasam, K. Søreide, M. Sparavigna, R. Spence, N. Spencer, H. Spiers, A. Spinelli, J. Sprakel, S. Sravanam, M. Srinivasan, R. Srinivasan, A. Staniszewska, S. J. Stanworth, K. Stasinos, R. J. C. Steele, I. Steinholt, M. Steinruecke, B. -J. Stephen, J. Stijns, M. Still, W. Stupalkowska, S. Subba, V. V. Subbotin, P. Sucharitkul, A. Sudarsanam, D. Sudhamsh Reddy, T. Suhardja, M. Suliman, M. Sund, A. Sunilkumar, N. Suresh, S. Sussmes, P. Sutton, J. Syltern, A. Taha, Y. Takamizawa, A. B. Takoutsing Dongmo, T. Tama´ s, L. Tan, J. L. Tan, K. Tan, E. Tan, A. Tan Yong Hui, A. Tanase, A. Tariverdiev, A. Tasnem, C. Tatar, E. Tay, P. Tejedor, G. Tesfaye, F. Tetinou, C. Thorpe, A. Thyø, D. Tlelo Amastal, M. Tolani, K. Tolga Saracoglu, T. To¨ lgyes, J. Tong, L. Torrent Jansa`, S. Toscano Igartua, M. R. Tovani Palone, H. Traff, J. Trevis, W. Tummers, A. Tur, I. Turchenko, V. Uche, A. Uddin, N. Udonsak, M. Ullah, T. Urbonas, C. Uwins, E. Uy Magadia, A. Uzair Qureshi, K. Uzun, P. Vadim, G. Valarche, R. A. Valdez Gonzalez, M. Vallee, D. -J. van Beek, A. S. van Dalen, D. van den Hondel, E. van der stok, M. van Dorp, S. van Oostendorp, E. van Praag, J. van Rees, L. van Silfhout, Z. Varga, S. Varghese, C. Varghese, J. Varghese, A. -M. Vasilica, X. Va´ squez Ojeda, E. Vega, S. Vehler, R. Venchiarutti, S. Vengatesan, M. Venn, D. Verma, G. Vianey Partida Nava, D. Victoria, P. Vieira, M. E. Vilar Alvarez, D. Vinci, G. Viscasillas Palla` s, M. Viswanath, J. Vivanco, V. Vizcaya Rodrı´guez, J. Vo, D. Volchanski, T. Voron, Y. Voronovskyi, J. Vu, M. Wadhwa, S. Wadhwa, G. Wagner, M. Wallace, Y. Y. Wang, J. Wang, A. Wani, K. Wanigasooriya, S. Wanjara, N. Wanjiku, C. Warner, T. Wei Leow, T. Weiser, M. Weisters, M. J. Wellington, C. Wells, C. Wenzelberg, D. Wettstein, A. Wezel, L. Wheldon, L. Widmer, M. Wilson, S. Wigmore, T. Wijayaratne, M. Wijeyaratne, B. P. L. 1176 | BJS, 2021, Vol. 108, No. 10 Sá-Marta, I. Sadien, D. SafariNteranya, K. Sagoo, S. Sakata, E. Saladino, A. Saleem, S. Saleem, M. Salehi, S. Salih, V. Sallinen, S. Salvans, Z. H. Sam, E. Samadov, M. Sampaio Alves, A. Sanad, S. Sánchez Wijnhoven, R. Wilkin, E. Williams, F. Willis, D. Winter, M. M. Wirsik, B. Wishah, G. Wong, W. J. Wong, K. Wong, K. -Y. Wong, D. Worku, E. Wright, J. Wright, O. Wroe Wright, S. Xenacki, W. Xia, W. Xu, Z. Xu, A. Yalcinkaya, W. Yang, P. -C. Yang, A. Yanishev, A. Yanzon de la Torre, H. Yao, E. Yaqoob, S. Yen Ling Quake, D. Yeo, B. Yeom, D. Yershov, M. Yiasemidou, A. Yildiz, A. Yiu, M. Yoav, E. Yong, R. Yoshimura, M. U. Younis, Z. Younis Ringshawl, M. Youssef, Y. Yue, S. Yuen, R. Yuldashev, C. Yurttas, B. Yves, A. Zaborowski, R. Zackeri, A. Zafar, W. Zahra, A. Zaidi, S. Zainudin, R. Zakeri, I. Zamora, A. T. Zamora, M. Zawistowski, G. Zbikowska, W. Zegers, S. Zehra, A. Zeyra, Z. Zhagniyev, L. G. Zhukova, M. Zivanovic, J. Zmuc, M. Zope, A. Zubayraeva, B. Zucker., Abahuje, E., Abbas, A., Abd El Aziz Abd El Maksoud, M., Abdelhady, A., Abdelhamid, S., Abdelkarem Ahmed Faraj, H., Abdelqader, B., Abdelrahman, T., Abdou, H., Abdullah, A., Abedua Harrison, M., Abem Owusu, E., Aboalazayem, A., Aboulhosn, R., Abu Oda, S., Abubakar, A., Abutaka, A., Acevedo Fontalvo, D., Acuna, S., Adefemi, A., Adegbola, S., Adenuga, T., Adeyeye, A., Adil Hilmi, A., K. Aditya, A. Adisa, Adjeso, T., Aftab, R., Afzal, A., Aggarwal, V., Aggarwal, A., Aguilera, R., Aguilera-Are´valo, M. -L., Aguirre Salamanca, E. J., Aguirre-Allende, I., Ahari, D., Ahmad, H., Ahmad Rauf, F., Ahmad Zartasht Khan, A., Ahmed, S., Ahmed Fieturi, N., Ahmed Mohamed, S., Ahmed-Bakhsh, Z., Ahsan Javed, M., Akano, L., Akbar, A., Akhbari, M., Akhmedov, P., Aksit, G., Akula, Y., Alagaratnam, A. S., Al Majid, S., Al Mukhtar, O., Al Omran, H., Alasali, N., Al-Azzawi, M., Al-Habsi, R., Al-Iraqi, H., Al-Naggar, H., Alameer, E., Albirnawi, H., Alderson, D., Aldulaijan, F., Alejandro Miranda Ojeda, R., Alhasan, A., Ali, S., Ali, A., Ali Khan, M., Alimova, Y., Aljanadi, F., Aljubure, R., Allopi, N., Almedbal, H., Almubarak, M., Alqaidoom, Z., Alselaim, N., Alshaar, M., Alshammari, R., Altaf, K., Altıner, S., Altunpak, B., Alvarez Lozada, L. A., Amal Nahal, E., Amer, A., Amin, K., Aminu, U., Amisi Numbi, N., Amjad, T., Amoah, R., An, Y., Anastasopoulos, N. -A., Andre´s Urrutia, J., Angarita, F., Angarita, K. -L., A´ ngel FreirI´a Eiras, M., Antypas, A., Anwar, M. A., Anwar, H., Apampa, T. O., Apostolou, K., Aquina, C., Arachchige Adithi Himika Randeni, R., Archila Godı´nez, M. I., Arez, O., Arezzo, A. A., Armonis, P., Arshad, S., Arshad Salman, M., Arshid, A., Arteaga Asensio, P. C., Arthur, T., Arumuga Jothi, A., Aryo Damara, F., Asensio Gomez, L., Ashcroft, J., Ashraf, S., Asif, A., Atif, M., Attaullah Khan, M., Avellaneda, N., Awad, S., Awadh, M., Axiaq, A., Ayad Mohammed Shuwayyah, A., Ayalew, D., Aytac, E., Azam, F., Azevedo, J., Azhar, B., Aziz, J., Aziz, A., Azzam, A., Baba Ndajiwo, A., Baig, M., Baker, D., Bakko, F., Balachandran, R., Balachandran, G., Balagizi Mudekereza, J., Balai, E., Balci, B., Balduzzi, A., Balhareth, A., Bandyopadhyay, S., Banerjee, D., Bangalore Mahalinga, D., Bankhead-Kendall, B., Bankole, N. D. A., Banwell, V., Baris Bengur, F., Baris Ozmen, B., Barnard, M., Barnett, R., Barreras Espinoza, J. A., Barrios, A., Bass, G., Bass, M., Bausys, A., Bavikatte, A., Bayram, J., Belousov, M., Berardi, A. G., Beamish, A., Beattie, C., Belia, F., Bellato, V., Bellikatti, S., Benjamens, S., Benlice, C., Bennedsgaard, S., Bennett, S., Bentounsi, Z., Bergenfeldt, H., Bergenfelz, A., Besselink, M., Bhandoria, G., Bhangu, E., Bhatia, M., Bhatti, M. T., Bilgili, Z., Bislenghi, G., Bisset, C., Biswas, S., Blake, J., Blanco, R., Boccalatte, L., Boden, R., Bojanic, C., Boland, M., Boland, P., Bollen, E., Bonci, E. -A., Boni, L., Booth, A., Booth, R., Borakati, A., Borunda Escudero, G. E., Bosco, S. J., Bostro¨ m, P., Botelho de Alencar Ferreira Cruz, P., Bouchagier, K., Bouhuwaish, A., Boutros, M., Boyce, K., Boyle, C., Bradshaw, L., Brandl, A., Brar, A., Brat, G., Brenkman, H., Brennan, C., Brines, C., Brookmyre, A., Brosnan, C., Brouwers, L., Brown, A., Brown, L., Brown, C., Brown, J., Bs, V., Buksh, M., Bunani Emmanuel, M., Burbano, D., Burelli, A., Burke, A., Burke, J., Burlov, N., Burns, A., Burton, O., Butt, A., Buzra Ozkan, B., Cabrera Silva, L., Caicedo, E. Y., Calderbank, T., Cambridge, W., Campelo, G., Can Tatar, O., Carbone, F., Carrano, F., Casallas, D., Casanova Portoles, D., Casciani, F., Cassimjee, I., Castaneda Ramı´rez, O. A., Catala´ n, V., Caviedes, J., Cayetano, L., ~ Ceresoli, M., Chan, M., Chan, V., Chandrasinghe, P., Chapman, S., Chaturvedi, A., Chaudhry, D., Chaudry, H., Chen, H. W., Cheng, A., Chernykh, M., Cherrie, A. M., Cheruiyot, I., Cheung, J., Chia, C., Chica, J., Chinai, N., Chirwa, A., Chiwaligo, J., Choi, A., Choi, J., Chowdhury, M. R., Christopher, E., Christou, N., Chu, T., Chua, D., Chua, H. W., Chung, C., Cihat Yildirim, A., Cillo, M., Cioffi, S., Claireaux, H., Clermonts, S., Clifford, R., Climent, M., Clynch, A., Coelen, R. -J., Cola´ s-Ruiz, E., Collar, A., Collard, M., Conlon, K. C., Connelly, T., Connor, K., Cook, J. A., Correia de Sa´, T., Cos¸gun Acar, N., Costa, T., Couch, D., Cowper, S., Creavin, B., Crook, B., Curell, A., D’Alessio, R., Dale, J., Damgaard Eriksen, J., Dario Martin Gonzalez, I., Darwish, A., Das, M., Das, R., Das, K., Dave, R., David, S. O., Davies, T., Davis, C., Davison, S., Davletshina, V., Dawidziuk, A., Dawson, A., de Andres Crespo, M., de Berker, H., de Dieu Ngo, P., Dekker, E., de la Caridad Espinosa Luis, R., de Lacy, B., Demartines, N., de Montserrat Medina Sifuentes, A., De Silva, S., del Rio, C., Delaune, V., Dell, A., Demirbas¸, I., Demirli Atici, S., Deniz Tepe, M., Derebey, M., Desai, G., Desai, M., Devarakonda, S., Deveras, N., Di Franco, G., Di Martino, M., Di Marzo, F., Dı´az, A´., Diaz del Gobbo, G., Diazcastrillon, C., Dick, L., Dickinson, K., Diego, E., Dimasi, I., Ding, A., Dingemans, S., Dixon, L., Dixon, B., Doherty, W., Dooreemeah, D., Donohue, C., Dornseifer, M., Dossa, F., Dossou, W., Drake, T., Drami, I., Drevin, G., du Plessis, M. C., Dudi-Venkata, N., Dudley, R., Duffy, S., Duklas, D., Dumbrava, B. -D., Duygu Avlar, F., Dworzynska, A., Ebrahim, W., Ebrahim, A., Efre´n Lozada Herna´ ndez, E., Ehigie, N., El Boghdady, M., El Hasnaoui, C., El Sheikh, M., El-Hussuna, A., Eldurssi, O., Elfeki, H., Elhadi, M., Elhassan, M., Elhissi, A., Elliot, B., Elsenbroek, C., Elsolh, B., Elson, N., Eltyeb, H., Emerson, H., Emile, S. H., Endalle, G., English, W., Ercisli, C., Espinosa, G., Essam Abdelraheem, M., Essangri, H., Etienne, P., Evans, M. D., Evans, T., Ezeme, C., Ezzahraa, F., Fadalla, T., Fagan, J., Fahmy, M., Fairfield, C., Falade, O., Famularo, S., Faqar-Uz-Zaman, F., Farid, Y., Farooq, A., Farooq, H., Farooqui, F., Farquharson, B., Faruqi, A., Faulder, R., Faut, M., Fechner, K., Feenstra, T., Fehervari, M., Fernandez, L., Ferna´ ndez Alberti, J., Ferrario, L., Field, D., Fiore, L., Fingerhut, S., Finlayson, S., Fleming, N., Fleming, C., Florial, E., Fok, M., Fokin, D., Foley, M., Forero, M. P., Forgan, T., Fornasiero, M., Fowler, H., Fowler, G., Franchi, E., Franklin, L., Fredriksson, A˚., Fruhling, P., Fuentes Navarrette, G., Fu¨ lo¨ p, A., Furtado, M., Gaarder, T., Galbraith, N., Gallagher, I. T. K., Gallo, G., Gana, T., Gaskin, E., Gasparini, M., Gatan, R. G., Geary, E., Gelaye Wudineh, K., Gemenetzis, G., Georgi, M., Ghalige, H., Ghareeb, W., Ghatwary Tantawy, T., Ghomsi, C., Ghuman, A., Giannakis, P., Giron, F., Gjengedal, K., Gkotsis, E., Glasbey, J., Godahewa, S., Godula, D., Goffredo, P., Goh, S., Golriz, M., Gomez, L., Gomez Gomez, D., Gonzalez, R., Gonzalez, D., Gonzalez Gutierrez, E., Gopar, D., Gordini, L., Gori, A., Gorta´ zar, S., Gousy, N., Gowda, R., Gowda, M., Gqada, J., Grechenig, M., Greer, J., Grego´ rio, L., Grigorova, A., Grimes, H., Groot, V., Grossman, R. C., Gruber, R., Gru¨ ter, A., Guest, R., Gujjuri, R., Gu¨ lc¸ek, E., Gulcu, B., Gull, K., Gulmez, M., Gupta, V., Gutlic, A., Guven, T., Gwatirisa, T., Gwini, G., Gwodog, P., Gysling, S., Habib, M., Hafeez Bhatti, A. B., Hallesmith, J., Halloran, S., Hamza Sadiq, M., Haney, C., Hanna, N., Hanna, L., Hannington, M., Harbjerg, J., Haribaskaran, D., Harran, N., Harrington, B., Harrison, E., Hasan, R., Hashmi, S., Hassan, M., Hassan, A., Haverkamp, L., Hazen, S., Heer, B., Heil, J., Helliwell, J., Henriksen, N., Henshall, D., Hermanson, M., Hermena, S., Hettiarachchi, D., Hextall, C., Hidalgo, M., Hidayat, H., Hider, A., Higgins, P., Hinchliffe, R., Hirani, D., Hirpara, D., Hisham, I., Hite, M., Hoh, S. M., Holmberg, C., Ho¨ lmich, E., Holst, F., Hossam, A., Hossam Elfallal, A., Howard, P., Huaman, E., Huang, Y., Huang, L., Huang, D., Huber, T., Hugh, J., Hughes, J., Hu¨ ttner, F., Huynh, R., Hylands, A., Iannuzzi, J., Ielpo, B., Iftikhar Talib, A., Ignacio, J., Ignatavicius, P., Ike, S., Ikwu, C., Inama, M., Ing, A., Ingels, A., Isik, A., Islam, N., Ives, I. J., Alhasan, A. J. M. S., Perez Rivera, C. J., Ja´ come, F., Jaffer, T., Jagiella-Lodise, O., Jain, M., Jain, K., Jakubauskas, M., Jalal, M., James, H., Jang, Y., Janssen, B., Jansson, H., Jariod-Ferrer, U´., Javanmard, H., Javed, S., Jayarajah, U., Jayasuriya, I., Je, J., Jessop, Z., Jia Lin Tang, E., Jiang, H., Jiayan, Y., Jih Huei, T., Jimenez-Rodriguez, R., Joh, D., Johnson, A., Jones, N., Jones, C., Jordan, C., Jose´ Nu´ nez Ju, J., Jose´ Pizarro, ~ M., Joseph, C. Jose Salazar J., Justiniano, C., Kabir, T., Kadhum, M., Kalfountzos, C., Kalogiannaki, E., Kalyanasundaram, K., Kamarajah, S., Kamil Quraishi, M., Kanemitsu, Y., Kapila, A., Kapila, V., Karagiannidis, G., Kashif, M., Kathiravelupillai, S., Kathiravelupillai, A., Katsogridakis, E., Kaur, K., Kaur Sekhon Inderjit Singh, H., Kausur, N., Kawka, M., Keehan, G., Kehlet Watt, S., Kelly, M., Kelly, M. E., Kelvin Egbuchulem, I., Kembuan, G., Khajeh, E., Khaled Elfaitur, A., Khan, M. F., Khan, S., Khan, M., Khan, D., Khan, H., Khatkar, H., Khatkov, E., Khaw, R., Kim, B., Kishore Siddiraju, K., Kitua, D., Kırımtay, B., Kmezic, S., Knight, S., Koe¨ter, T., Koh, A., Koh Hong Xiang, F., Kojo Anyomih, T., Kok, A. I. N., Kokelaar, R., Koliarakis, I., Kolli, S., Kong, J., Ko¨ nig, D., Otze, M., Kourdouli, A., Kowal, M., Kraima, A., Kramer, F., Kryzauskas, M., Kuchynskyi, I., Kuemmerli, C., Kuiper, S., Kumar, S., Kumar, A., Kumar, L., Kumar, H., Kumar, N., Kumar Bandyopadhyay, S., Kumar Garg, P., Kumar Venkatappa, S., Kung, J., Kural, S., Kushairi, A., Kuuzie, E., Kvietkauskas, M., Kwek, I., La, J., Lai, L., Lakpriya, S., Lam, K., Lami, M., Lansdorp-Vogelaar, I., Lapolla, P., Larsen, H., Latif, J., Laudari, U., Laurnezi, A., Lawal, A., Lawday, S., Lederhuber, H., Lednev, A., Lee, R., van Leerdam, M. E., Lefevbre, G., Lesmus, M., Leyva Moraga, F. A., Leyva Moraga, E., Leyva Moraga, F., Li, H. L., Li, A., Li, Z., Licardie, E., Light, A., Lightner, A. L., Lin, A., Lincango, E., Litta, F., Liu, H., Lofthouse, B., Londono, M. A., Lopes, R., Lopes de Freitas, R., Lopez, L., Lo´ pez, A. I., ~ Lopez-Gomez, J., Lopez-Pena, G., Lowe, R., Lowe, D., Lowey, M., Loy, G., Lozanovski, V., Luzon, J., Lynn, P., Maccabe, T., Machielsen, A., Mafla Herrerı´a, C. A., Maggino, L., Mahawar, K., Mahmood, D., Mahmoud, M., Mahtani, K., Maitra, I., Maji, S., Majiet, I., Mal, L., Malherbe, J., Malhotra, K., Malkomes, P., Man, E., Manan Sheikh, A., Manjunath, S., Manzano Nunez, R., Manzoor, S., Maqsood, R., ~ Marchegiani, G., Marchegiani, F., Marı´n, D., Marin, A., Marks, I., Marson, E., Martensen, A., Martin, D., Martı´n Martı´n, G., Martin-Perez, B., Martinez, P., Marwaha, P., Mashauri, C., Mashbari, H., Masior, Ł., Masri, R., Masud, L., Masudi, S., Mateu Calabuig, G., Math, S., Matrachisia, A., Mayol, J., Mazingi, D., Mazzotta, A., Mcalinden, J., Mccabe, G., Mccolm, L., Mcelvaney, H., Mcgivern, K., Mcgovern, J., Mcguinness, E., Mcinerney, N., Mckay, S., Mckee, C., Mckenna, M., Mckenna, N., Mclean, K., Mediratta, S., Medkova, Y., Medzhidov, O., Mehraj, A., Mekhael, M., Mekinde, O., Mellenthin, C., Melucci, A., Mentor, K., Merchant, J., Messias, H., Messeha, M., Meza, C., Mhango, P., Miladinov, M., Milagros Niquen Jimenez, M., Miller, P., Mills, E., Milton, A., Minayeva, O. A., MinHua Zheng, Z., Mischlinger, H., Mo¨ ckli, B., Modi, R., Mohamed, H. M., Mohamed, M., Mohamed Abulghasm, T., Mohammad, S. A., Mohammed, T. O., Mohammed, A., Mohan, H., Mohan, M., Moin, I., Mok, V., Molina, G., Moloney, J., Moneim, J., Monfort Mira, M., Montcusı´ Ventura, B., Montouri, M., Moossdorff, M., Mora-Guzma´ n, I., Moran, B., Mora´ n, R. A. R., Moreno-Ordaz, S., Morera, A´., Morgan, R., Morley, R., Moro-Valdezate, D., Moros, S., Moss, J. -L., Morven, A., Morton, D., Moynihan, A., Moyo´ n, M., Muduli, N., Mugla, N., Mugla, W., Mu¨ ller, P., Mun, G., Mundhada, R., Munir, I., Munoz, F., Mu ~ noz, E., Mu ~ noz, A., Munoz Balderas, D. ~ C., Murgitroyd, E., Murray, V., Murthy, S., ~ Mushiwokufa, W., Mustafa, H., Mustakimov, B., Mutambanengwe, P., Myint, P., Nadkarni, S., Naess, P. A., Nahar, S., Naidoo, P., Nam, R., Nandhra, S., Nanjappa, N., Narasimhan, V., Nardi, W., Nasir, M., Naughton, A., Naumann, D., Navarro, S., Nawaaz Karimbocus, M., Nazir, A., Ndereya, S., Ndong, A., Negoi, I., Nel, D., Nelson, D., Nepal, S., Nugent, T., Nepogodiev, D., Neufeld, J., Ng, J., Ng, D., Ng, C. E., Ngaserin, S., Ngu, L., Ngwenya, E., Fhearaigh, R. N., Nikolousakis, T. -K., Ninkovic, M., Nita, G., Nitschke, C., Noren, E., Noton, T., Novikova, A., Nowinka, Z., Nyakunengwa, T., Nyalundja, A., Nzenwa, I., Ø Kristensen, H., O’Brien, C., O’Brien, L., O’Brien, S., O’Reilly, J., O’Rourke, S., O’Sullivan, M., O’Dwyer, M., Ochieng, L., Oderoha, E., Oh, K. E., O¨ hlberger, L., O¨ lc¸u¨ m, M., Olkina, A., Omkumar, M., Omnitel, B., Oncel Yakar, D., Ong, K., Ong Wei Lin, L., Ooi, R., Ooi, S., Oomman, A., Oon Tyjet, D., Opiyo, S., Oscullo Yepez, J. J., Osei-kuffour, N., Osunronbi, T., Ottlaka´ n, A., Oussama Kacimi, S., Ovaere, S., Ozair, A., Pachler, F., Pai Oo, S., Paiella, S., Panaiotti, L., Panda, N., Pandarinath, S., Pandey, D., Pandrowala, S., Papa Mamadou, F., Paranathala, M., Park, J., Parmar, C., Parvez, A., Pasovic, L., Pasquer, A., Pasumarthy, N., Pata, F., Patel, T., Patel, P., Patel, N., Patel, M., Patron Uriburu, N., Patrone, R., Paul, A., Pavan Kumar, O. M., Pavithran, A., Pedraza Ciro, M., Pellino, G., Peloso, A., Pena~ Gallardo, M. T., Pena Velazquez, A., Perea, J., Pe´rez-Sa´ nchez, L. E., ~ Perra, T., Perrotta, G., Petersson, P., Petra, G., Petrucciani, N., Pickin, C., Pino, V., Pinotti, E., Pinto, F., Plum, P., Podesta, F., Pollini, T., Pompeu Sa´, M., Ponce Leon, F., Ponniah, H. S., Ponte de Sousa, X., Ponton, J., Pontula, A., Popa, M., Portilla, A. L., Posner, F., Post, S., Potolicchio, A., Pouwels, S., Povo, A., Prasad, P., Preciado, S., Preece, R., Proud, D., Pulido Segura, J. A., Puliyath, N., Qui, M., Quimbaya Rodrı´guez, A. S., Raby-Smith, W., Racovit¸a, A., Rad, A., Radwan, R., Rafaih Iqbal, M., Rafik, A., Raguan, B., Rahi, M., Rahiri, J. -L., Rahme, J., Rai, L., Raj, A., Raj Saksena, A., Raja, M., Ramirez, J., Ramzi, J., Ranstam, J., Rao, C., Rashid, A., Ratnayake, B., Rattanasirivilai, K., Raubenheimer, K., Ravikumar, N., Ravn, S., Razoz, N., Rea, W., Regan, A., Rela, M., Remme, A., Rey Chaves, C. E., Reyes, A., Riad, A., Rice, D., Rios Quintana, K., Ritter, A., Roalsø, M., Robinson, D., Rodriguez, J., Rodrı´guez, F., Rodriguez, M. C., Rogers, A., Rohila, J., Romanyuc, D., Romic, I., Rommaneh, M., Rompianesi, G., Rosa, F., Roscio, F., Rose, A., Rotimi, T., Ruiz, H., Ruiz Yucuma, J., Ruiz-U´ car, E., Ruslan, M., Rutega˚ rd, M., Ryan Harper, E., Ryckx, A., Rydbeck, D., Fonseca, E., Sanchez Teran, A., Sanchez Ussa, S., Sandli, O., Sanfey, H., Sanghera, J., Sani, I., Santafe Guerrero, M., Sante Fornasiero, M., Santes Jasso, O., Santos Pereira, I., Santos Sousa, H., Saratzis, A., Sarmiento Alarcon, A., Saumtally, T., Sayyed, R., Schettino, M., Schleimer, L., Schmidt, T., Schondffelt, K., Schwab, M., Scott, A., Searle, H., Sebopelo, L., Seeglier, B., Seishima, R., Semenvov, D., Senent-Boza, A., Sepulveda, J., Serenari, M., Serrano Navidad, M., Sert, I., Sewart, E., Sgro`, A., Shadrina, V., Shah, K., Shahid, F., Shalaby, M., Shankar, B., Shapiro, J., Sharma, L., Sheel, A., Shenfine, A., Shenoy, S., Sherif, A., Shetty, N., Shetty, R., Sia, T. C., Sichimba, D., Siddique, H., Siddiqui, I., Simkens, G., Simoe, J., Simon, H., Sinan, L., Singh, T., Singh, K., Singh, Y., Sinha, L., Siragusa, L., Sluckin, T., Smart, Y. W., Smith, H., Smith, K., Smits, L., Sneep-van Kessel, C., Sohrabi, C., Solo´ rzano Pineda, O., Soma, A., Sooriyapiragasam, L., Søreide, K., Sparavigna, M., Spence, R., Spencer, N., Spiers, H., Spinelli, A., Sprakel, J., Sravanam, S., Srinivasan, M., Srinivasan, R., Staniszewska, A., Stanworth, S. J., Stasinos, K., Steele, R. J. C., Steinholt, I., Steinruecke, M., Stephen, B. -J., Stijns, J., Still, M., Stupalkowska, W., Subba, S., Subbotin, V. V., Sucharitkul, P., Sudarsanam, A., Sudhamsh Reddy, D., Suhardja, T., Suliman, M., Sund, M., Sunilkumar, A., Suresh, N., Sussmes, S., Sutton, P., Syltern, J., Taha, A., Takamizawa, Y., Takoutsing Dongmo, A. B., Tama´ s, T., Tan, L., Tan, J. L., Tan, K., Tan, E., Tan Yong Hui, A., Tanase, A., Tariverdiev, A., Tasnem, A., Tatar, C., Tay, E., Tejedor, P., Tesfaye, G., Tetinou, F., Thorpe, C., Thyø, A., Tlelo Amastal, D., Tolani, M., Tolga Saracoglu, K., To¨ lgyes, T., Tong, J., Torrent Jansa`, L., Toscano Igartua, S., Tovani Palone, M. R., Traff, H., Trevis, J., Tummers, W., Tur, A., Turchenko, I., Uche, V., Uddin, A., Udonsak, N., Ullah, M., Urbonas, T., Uwins, C., Uy Magadia, E., Uzair Qureshi, A., Uzun, K., Vadim, P., Valarche, G., Valdez Gonzalez, R. A., Vallee, M., van Beek, D. -J., van Dalen, A. S., van den Hondel, D., van der stok, E., van Dorp, M., van Oostendorp, S., van Praag, E., van Rees, J., van Silfhout, L., Varga, Z., Varghese, S., Varghese, C., Varghese, J., Vasilica, A. -M., Va´ squez Ojeda, X., Vega, E., Vehler, S., Venchiarutti, R., Vengatesan, S., Venn, M., Verma, D., Vianey Partida Nava, G., Victoria, D., Vieira, P., Vilar Alvarez, M. E., Vinci, D., Viscasillas Palla` s, G., Viswanath, M., Vivanco, J., Vizcaya Rodrı´guez, V., Vo, J., Volchanski, D., Voron, T., Voronovskyi, Y., Vu, J., Wadhwa, M., Wadhwa, S., Wagner, G., Wallace, M., Wang, Y. Y., Wang, J., Wani, A., Wanigasooriya, K., Wanjara, S., Wanjiku, N., Warner, C., Wei Leow, T., Weiser, T., Weisters, M., Wellington, M. J., Wells, C., Wenzelberg, C., Wettstein, D., Wezel, A., Wheldon, L., Widmer, L., Wilson, M., Wigmore, S., Wijayaratne, T., Wijeyaratne, M., 1176 | BJS, B. P. L., 108, Vol., 10 Sá-Marta, No., Sadien, I., Safarinteranya, D., Sagoo, K., Sakata, S., Saladino, E., Saleem, A., Saleem, S., Salehi, M., Salih, S., Sallinen, V., Salvans, S., Sam, Z. H., Samadov, E., Sampaio Alves, M., Sanad, A., Sánchez Wijnhoven, S., Wilkin, R., Williams, E., Willis, F., Winter, D., Wirsik, M. M., Wishah, B., Wong, G., Wong, W. J., Wong, K., Wong, K. -Y., Worku, D., Wright, E., Wright, J., Wroe Wright, O., Xenacki, S., Xia, W., Xu, W., Xu, Z., Yalcinkaya, A., Yang, W., Yang, P. -C., Yanishev, A., Yanzon de la Torre, A., Yao, H., Yaqoob, E., Yen Ling Quake, S., Yeo, D., Yeom, B., Yershov, D., Yiasemidou, M., Yildiz, A., Yiu, A., Yoav, M., Yong, E., Yoshimura, R., Younis, M. U., Younis Ringshawl, Z., Youssef, M., Yue, Y., Yuen, S., Yuldashev, R., Yurttas, C., Yves, B., Zaborowski, A., Zackeri, R., Zafar, A., Zahra, W., Zaidi, A., Zainudin, S., Zakeri, R., Zamora, I., Zamora, A. T., Zawistowski, M., Zbikowska, G., Zegers, W., Zehra, S., Zeyra, A., Zhagniyev, Z., Zhukova, L. G., Zivanovic, M., Zmuc, J., Zope, M., Zubayraeva, A., Zucker., B., Abahuje, E, Abbas, A, Abd El Aziz Abd El Maksoud, M, Abdelhady, A, Abdelhamid, S, Abdelkarem Ahmed Faraj, H, Abdelqader, B, Abdelrahman, T, Abdou, H, Abdullah, A, Abedua Harrison, M, Abem Owusu, E, Aboalazayem, A, Aboulhosn, R, Abu Oda, S, Abubakar, A, Abutaka, A, Acevedo Fontalvo, D, Acuna, S, Adefemi, A, Adegbola, S, Adenuga, T, Adeyeye, A, Adil Hilmi, A, Adisa, A, Aditya, K, Adjeso, T, Aftab, R, Afzal, A, Aggarwal, V, Aggarwal, A, Aguilera, R, Aguilera-Arevalo, M, Aguirre Salamanca, E, Aguirre-Allende, I, Ahari, D, Ahmad, H, Ahmad Rauf, F, Ahmad Zartasht Khan, A, Ahmed, S, Ahmed Fieturi, N, Ahmed Mohamed, S, Ahmed-Bakhsh, Z, Ahsan Javed, M, Akano, L, Akbar, A, Akhbari, M, Akhmedov, P, Aksit, G, Akula, Y, Alagaratnam, A, Al Majid, S, Al Mukhtar, O, Al Omran, H, Alasali, N, Al-Azzawi, M, Al-Habsi, R, Al-Iraqi, H, Al-Naggar, H, Alameer, E, Albirnawi, H, Alderson, D, Aldulaijan, F, Alejandro Miranda Ojeda, R, Alhasan, A, Ali, S, Ali, A, Ali Khan, M, Alimova, Y, Aljanadi, F, Aljubure, R, Allopi, N, Almedbal, H, Almubarak, M, Alqaidoom, Z, Alselaim, N, Alshaar, M, Alshammari, R, Altaf, K, Altiner, S, Altunpak, B, Alvarez Lozada, L, Amal Nahal, E, Amer, A, Amin, K, Aminu, U, Amisi Numbi, N, Amjad, T, Amoah, R, An, Y, Anastasopoulos, N, Andres Urrutia, J, Angarita, F, Angarita, K, Angel Freiria Eiras, M, Antypas, A, Anwar, M, Anwar, H, Apampa, T, Apostolou, K, Aquina, C, Arachchige Adithi Himika Randeni, R, Archila Godinez, M, Arez, O, Arezzo, A, Armonis, P, Arshad, S, Arshad Salman, M, Arshid, A, Arteaga Asensio, P, Arthur, T, Arumuga Jothi, A, Aryo Damara, F, Asensio Gomez, L, Ashcroft, J, Ashraf, S, Asif, A, Atif, M, Attaullah Khan, M, Avellaneda, N, Awad, S, Awadh, M, Axiaq, A, Ayad Mohammed Shuwayyah, A, Ayalew, D, Aytac, E, Azam, F, Azevedo, J, Azhar, B, Aziz, J, Aziz, A, Azzam, A, Baba Ndajiwo, A, Baig, M, Baker, D, Bakko, F, Balachandran, R, Balachandran, G, Balagizi Mudekereza, J, Balai, E, Balci, B, Balduzzi, A, Balhareth, A, Bandyopadhyay, S, Banerjee, D, Bangalore Mahalinga, D, Bankhead-Kendall, B, Bankole, N, Banwell, V, Baris Bengur, F, Baris Ozmen, B, Barnard, M, Barnett, R, Barreras Espinoza, J, Barrios, A, Bass, G, Bass, M, Bausys, A, Bavikatte, A, Bayram, J, Belousov, M, Berardi, A, Beamish, A, Beattie, C, Belia, F, Bellato, V, Bellikatti, S, Benjamens, S, Benlice, C, Bennedsgaard, S, Bennett, S, Bentounsi, Z, Bergenfeldt, H, Bergenfelz, A, Besselink, M, Bhandoria, G, Bhangu, E, Bhatia, M, Bhatti, M, Bilgili, Z, Bislenghi, G, Bisset, C, Biswas, S, Blake, J, Blanco, R, Boccalatte, L, Boden, R, Bojanic, C, Boland, M, Boland, P, Bollen, E, Bonci, E, Boni, L, Booth, A, Booth, R, Borakati, A, Borunda Escudero, G, Bosco, S, Bostrom, P, Botelho De Alencar Ferreira Cruz, P, Bouchagier, K, Bouhuwaish, A, Boutros, M, Boyce, K, Boyle, C, Bradshaw, L, Brandl, A, Brar, A, Brat, G, Brenkman, H, Brennan, C, Brines, C, Brookmyre, A, Brosnan, C, Brouwers, L, Brown, A, Brown, L, Brown, C, Brown, J, Bs, V, Buksh, M, Bunani Emmanuel, M, Burbano, D, Burelli, A, Burke, A, Burke, J, Burlov, N, Burns, A, Burton, O, Butt, A, Buzra Ozkan, B, Cabrera Silva, L, Caicedo, E, Calderbank, T, Cambridge, W, Campelo, G, Can Tatar, O, Carbone, F, Carrano, F, Casallas, D, Casanova Portoles, D, Casciani, F, Cassimjee, I, Castaneda Ramirez, O, Catalan, V, Caviedes, J, Cayetano, L, Ceresoli, M, Chan, M, Chan, V, Chandrasinghe, P, Chapman, S, Chaturvedi, A, Chaudhry, D, Chaudry, H, Chen, H, Cheng, A, Chernykh, M, Cherrie, A, Cheruiyot, I, Cheung, J, Chia, C, Chica, J, Chinai, N, Chirwa, A, Chiwaligo, J, Choi, A, Choi, J, Chowdhury, M, Christopher, E, Christou, N, Chu, T, Chua, D, Chua, H, Chung, C, Cihat Yildirim, A, Cillo, M, Cioffi, S, Claireaux, H, Clermonts, S, Clifford, R, Climent, M, Clynch, A, Coelen, R, Colas-Ruiz, E, Collar, A, Collard, M, Conlon, K, Connelly, T, Connor, K, Cook, J, Correia De Sa, T, Cosgun Acar, N, Costa, T, Couch, D, Cowper, S, Creavin, B, Crook, B, Curell, A, D'Alessio, R, Dale, J, Damgaard Eriksen, J, Dario Martin Gonzalez, I, Darwish, A, Das, M, Das, R, Das, K, Dave, R, David, S, Davies, T, Davis, C, Davison, S, Davletshina, V, Dawidziuk, A, Dawson, A, De Andres Crespo, M, De Berker, H, De Dieu Ngo, P, Dekker, E, De La Caridad Espinosa Luis, R, De Lacy, B, Demartines, N, De Montserrat Medina Sifuentes, A, De Silva, S, Del Rio, C, Delaune, V, Dell, A, Demirbas, I, Demirli Atici, S, Deniz Tepe, M, Derebey, M, Desai, G, Desai, M, Devarakonda, S, Deveras, N, Di Franco, G, Di Martino, M, Di Marzo, F, Diaz, A, Diaz Del Gobbo, G, Diazcastrillon, C, Dick, L, Dickinson, K, Diego, E, Dimasi, I, Ding, A, Dingemans, S, Dixon, L, Dixon, B, Doherty, W, Dooreemeah, D, Donohue, C, Dornseifer, M, Dossa, F, Dossou, W, Drake, T, Drami, I, Drevin, G, Du Plessis, M, Dudi-Venkata, N, Dudley, R, Duffy, S, Duklas, D, Dumbrava, B, Duygu Avlar, F, Dworzynska, A, Ebrahim, W, Ebrahim, A, Efren Lozada Hernandez, E, Ehigie, N, El Boghdady, M, El Hasnaoui, C, El Sheikh, M, El-Hussuna, A, Eldurssi, O, Elfeki, H, Elhadi, M, Elhassan, M, Elhissi, A, Elliot, B, Elsenbroek, C, Elsolh, B, Elson, N, Eltyeb, H, Emerson, H, Emile, S, Endalle, G, English, W, Ercisli, C, Espinosa, G, Essam Abdelraheem, M, Essangri, H, Etienne, P, Evans, M, Evans, T, Ezeme, C, Ezzahraa, F, Fadalla, T, Fagan, J, Fahmy, M, Fairfield, C, Falade, O, Famularo, S, Faqar-Uz-Zaman, F, Farid, Y, Farooq, A, Farooq, H, Farooqui, F, Farquharson, B, Faruqi, A, Faulder, R, Faut, M, Fechner, K, Feenstra, T, Fehervari, M, Fernandez, L, Fernandez Alberti, J, Ferrario, L, Field, D, Fiore, L, Fingerhut, S, Finlayson, S, Fleming, N, Fleming, C, Florial, E, Fok, M, Fokin, D, Foley, M, Forero, M, Forgan, T, Fornasiero, M, Fowler, H, Fowler, G, Franchi, E, Franklin, L, Fredriksson, A, Fruhling, P, Fuentes Navarrette, G, Fulop, A, Furtado, M, Gaarder, T, Galbraith, N, Gallagher, I, Gallo, G, Gana, T, Gaskin, E, Gasparini, M, Gatan, R, Geary, E, Gelaye Wudineh, K, Gemenetzis, G, Georgi, M, Ghalige, H, Ghareeb, W, Ghatwary Tantawy, T, Ghomsi, C, Ghuman, A, Giannakis, P, Giron, F, Gjengedal, K, Gkotsis, E, Glasbey, J, Godahewa, S, Godula, D, Goffredo, P, Goh, S, Golriz, M, Gomez, L, Gomez Gomez, D, Gonzalez, R, Gonzalez, D, Gonzalez Gutierrez, E, Gopar, D, Gordini, L, Gori, A, Gortazar, S, Gousy, N, Gowda, R, Gowda, M, Gqada, J, Grechenig, M, Greer, J, Gregorio, L, Grigorova, A, Grimes, H, Groot, V, Grossman, R, Gruber, R, Gruter, A, Guest, R, Gujjuri, R, Gulcek, E, Gulcu, B, Gull, K, Gulmez, M, Gupta, V, Gutlic, A, Guven, T, Gwatirisa, T, Gwini, G, Gwodog, P, Gysling, S, Habib, M, Hafeez Bhatti, A, Hallesmith, J, Halloran, S, Hamza Sadiq, M, Haney, C, Hanna, N, Hanna, L, Hannington, M, Harbjerg, J, Haribaskaran, D, Harran, N, Harrington, B, Harrison, E, Hasan, R, Hashmi, S, Hassan, M, Hassan, A, Haverkamp, L, Hazen, S, Heer, B, Heil, J, Helliwell, J, Henriksen, N, Henshall, D, Hermanson, M, Hermena, S, Hettiarachchi, D, Hextall, C, Hidalgo, M, Hidayat, H, Hider, A, Higgins, P, Hinchliffe, R, Hirani, D, Hirpara, D, Hisham, I, Hite, M, Hoh, S, Holmberg, C, Holmich, E, Holst, F, Hossam, A, Hossam Elfallal, A, Howard, P, Huaman, E, Huang, Y, Huang, L, Huang, D, Huber, T, Hugh, J, Hughes, J, Huttner, F, Huynh, R, Hylands, A, Iannuzzi, J, Ielpo, B, Iftikhar Talib, A, Ignacio, J, Ignatavicius, P, Ike, S, Ikwu, C, Inama, M, Ing, A, Ingels, A, Isik, A, Islam, N, Ives, I, Al-Hasan, A, Perez Rivera, C, Jacome, F, Jaffer, T, Jagiella-Lodise, O, Jain, M, Jain, K, Jakubauskas, M, Jalal, M, James, H, Jang, Y, Janssen, B, Jansson, H, Jariod-Ferrer, U, Javanmard, H, Javed, S, Jayarajah, U, Jayasuriya, I, Je, J, Jessop, Z, Jia Lin Tang, E, Jiang, H, Jiayan, Y, Jih Huei, T, Jimenez-Rodriguez, R, Joh, D, Johnson, A, Jones, N, Jones, C, Jordan, C, Jose Nunez Ju, J, Jose Pizarro, M, Jose Salazar, C, Joseph, J, Justiniano, C, Kabir, T, Kadhum, M, Kalfountzos, C, Kalogiannaki, E, Kalyanasundaram, K, Kamarajah, S, Kamil Quraishi, M, Kanemitsu, Y, Kapila, A, Kapila, V, Karagiannidis, G, Kashif, M, Kathiravelupillai, S, Kathiravelupillai, A, Katsogridakis, E, Kaur, K, Kaur Sekhon Inderjit Singh, H, Kausur, N, Kawka, M, Keehan, G, Kehlet Watt, S, Kelly, M, Kelvin Egbuchulem, I, Kembuan, G, Khajeh, E, Khaled Elfaitur, A, Khan, M, Khan, S, Khan, D, Khan, H, Khatkar, H, Khatkov, E, Khaw, R, Kim, B, Kishore Siddiraju, K, Kitua, D, Kirimtay, B, Kmezic, S, Knight, S, Koeter, T, Koh, A, Koh Hong Xiang, F, Kojo Anyomih, T, Kok, A, Kokelaar, R, Koliarakis, I, Kolli, S, Kong, J, Konig, D, Koshy, M, Kotze, P, Kourdouli, A, Kowal, M, Kraima, A, Kramer, F, Kryzauskas, M, Kuchynskyi, I, Kuemmerli, C, Kuiper, S, Kumar, S, Kumar, A, Kumar, L, Kumar, H, Kumar, N, Kumar Bandyopadhyay, S, Kumar Garg, P, Kumar Venkatappa, S, Kung, J, Kural, S, Kushairi, A, Kuuzie, E, Kvietkauskas, M, Kwek, I, La, J, Lai, L, Lakpriya, S, Lam, K, Lami, M, Lansdorp-Vogelaar, I, Lapolla, P, Larsen, H, Latif, J, Laudari, U, Laurnezi, A, Lawal, A, Lawday, S, Lederhuber, H, Lednev, A, Lee, R, Van Leerdam, M, Lefevbre, G, Lesmus, M, Leyva Moraga, F, Leyva Moraga, E, Li, H, Li, A, Li, Z, Licardie, E, Light, A, Lightner, A, Lin, A, Lincango, E, Litta, F, Liu, H, Lofthouse, B, Londono, M, Lopes, R, Lopes De Freitas, R, Lopez, L, Lopez, A, Lopez-Gomez, J, Lopez-Pena, G, Lowe, R, Lowe, D, Lowey, M, Loy, G, Lozanovski, V, Luzon, J, Lynn, P, Maccabe, T, Machielsen, A, Mafla Herreria, C, Maggino, L, Mahawar, K, Mahmood, D, Mahmoud, M, Mahtani, K, Maitra, I, Maji, S, Majiet, I, Mal, L, Malherbe, J, Malhotra, K, Malkomes, P, Man, E, Manan Sheikh, A, Manjunath, S, Manzano Nunez, R, Manzoor, S, Maqsood, R, Marchegiani, G, Marchegiani, F, Marin, D, Marin, A, Marks, I, Marson, E, Martensen, A, Martin, D, Martin Martin, G, Martin-Perez, B, Martinez, P, Marwaha, P, Mashauri, C, Mashbari, H, Masior, L, Masri, R, Masud, L, Masudi, S, Mateu Calabuig, G, Math, S, Matrachisia, A, Mayol, J, Mazingi, D, Mazzotta, A, Mcalinden, J, Mccabe, G, Mccolm, L, Mcelvaney, H, Mcgivern, K, Mcgovern, J, Mcguinness, E, Mcinerney, N, Mckay, S, Mckee, C, Mckenna, M, Mckenna, N, Mclean, K, Mediratta, S, Medkova, Y, Medzhidov, O, Mehraj, A, Mekhael, M, Mekinde, O, Mellenthin, C, Melucci, A, Mentor, K, Merchant, J, Messias, H, Messeha, M, Meza, C, Mhango, P, Miladinov, M, Milagros Niquen Jimenez, M, Miller, P, Mills, E, Milton, A, Minayeva, O, MinHua Zheng, Z, Mischlinger, H, Mockli, B, Modi, R, Mohamed, H, Mohamed, M, Mohamed Abulghasm, T, Mohammad, S, Mohammed, T, Mohammed, A, Mohan, H, Mohan, M, Moin, I, Mok, V, Molina, G, Moloney, J, Moneim, J, Monfort Mira, M, Montcusi Ventura, B, Montouri, M, Moossdorff, M, Mora-Guzman, I, Moran, B, Moran, R, Moreno-Ordaz, S, Morera, A, Morgan, R, Morley, R, Moro-Valdezate, D, Moros, S, Moss, J, Morven, A, Morton, D, Moynihan, A, Moyon, M, Muduli, N, Mugla, N, Mugla, W, Muller, P, Mun, G, Mundhada, R, Munir, I, Munoz, F, Munoz, E, Munoz, A, Munoz Balderas, D, Murgitroyd, E, Murray, V, Murthy, S, Mushiwokufa, W, Mustafa, H, Mustakimov, B, Mutambanengwe, P, Myint, P, Nadkarni, S, Naess, P, Nahar, S, Naidoo, P, Nam, R, Nandhra, S, Nanjappa, N, Narasimhan, V, Nardi, W, Nasir, M, Naughton, A, Naumann, D, Navarro, S, Nawaaz Karimbocus, M, Nazir, A, Ndereya, S, Ndong, A, Negoi, I, Nel, D, Nelson, D, Nepal, S, Nugent, T, Nepogodiev, D, Neufeld, J, Ng, J, Ng, D, Ng, C, Ngaserin, S, Ngu, L, Ngwenya, E, Fhearaigh, R, Nikolousakis, T, Ninkovic, M, Nita, G, Nitschke, C, Noren, E, Noton, T, Novikova, A, Nowinka, Z, Nyakunengwa, T, Nyalundja, A, Nzenwa, I, Kristensen, H, O'Brien, C, O'Brien, L, O'Brien, S, O'Reilly, J, O'Rourke, S, O'Sullivan, M, O'Dwyer, M, Ochieng, L, Oderoha, E, Oh, K, Ohlberger, L, Olcum, M, Olkina, A, Omkumar, M, Omnitel, B, Oncel Yakar, D, Ong, K, Ong Wei Lin, L, Ooi, R, Ooi, S, Oomman, A, Oon Tyjet, D, Opiyo, S, Oscullo Yepez, J, Osei-Kuffour, N, Osunronbi, T, Ottlakan, A, Oussama Kacimi, S, Ovaere, S, Ozair, A, Pachler, F, Pai Oo, S, Paiella, S, Panaiotti, L, Panda, N, Pandarinath, S, Pandey, D, Pandrowala, S, Papa Mamadou, F, Paranathala, M, Park, J, Parmar, C, Parvez, A, Pasovic, L, Pasquer, A, Pasumarthy, N, Pata, F, Patel, T, Patel, P, Patel, N, Patel, M, Patron Uriburu, N, Patrone, R, Paul, A, Pavan Kumar, O, Pavithran, A, Pedraza Ciro, M, Pellino, G, Peloso, A, Pena Gallardo, M, Pena Velazquez, A, Perea, J, Perez-Sanchez, L, Perra, T, Perrotta, G, Petersson, P, Petra, G, Petrucciani, N, Pickin, C, Pino, V, Pinotti, E, Pinto, F, Plum, P, Podesta, F, Pollini, T, Pompeu Sa, M, Ponce Leon, F, Ponniah, H, Ponte De Sousa, X, Ponton, J, Pontula, A, Popa, M, Portilla, A, Posner, F, Post, S, Potolicchio, A, Pouwels, S, Povo, A, Prasad, P, Preciado, S, Preece, R, Proud, D, Pulido Segura, J, Puliyath, N, Qui, M, Quimbaya Rodriguez, A, Raby-Smith, W, Racovita, A, Rad, A, Radwan, R, Rafaih Iqbal, M, Rafik, A, Raguan, B, Rahi, M, Rahiri, J, Rahme, J, Rai, L, Raj, A, Raj Saksena, A, Raja, M, Ramirez, J, Ramzi, J, Ranstam, J, Rao, C, Rashid, A, Ratnayake, B, Rattanasirivilai, K, Raubenheimer, K, Ravikumar, N, Ravn, S, Razoz, N, Rea, W, Regan, A, Rela, M, Remme, A, Rey Chaves, C, Reyes, A, Riad, A, Rice, D, Rios Quintana, K, Ritter, A, Roalso, M, Robinson, D, Rodriguez, J, Rodriguez, F, Rodriguez, M, Rogers, A, Rohila, J, Romanyuc, D, Romic, I, Rommaneh, M, Rompianesi, G, Rosa, F, Roscio, F, Rose, A, Rotimi, T, Ruiz, H, Ruiz Yucuma, J, Ruiz-Ucar, E, Ruslan, M, Rutegard, M, Ryan Harper, E, Ryckx, A, Rydbeck, D, Sa-Marta, E, Sadien, I, Safari Nteranya, D, Sagoo, K, Sakata, S, Saladino, E, Saleem, A, Saleem, S, Salehi, M, Salih, S, Sallinen, V, Salvans, S, Sam, Z, Samadov, E, Sampaio Alves, M, Sanad, A, Sanchez Fonseca, S, Sanchez Teran, A, Sanchez Ussa, S, Sandli, O, Sanfey, H, Sanghera, J, Sani, I, Santafe Guerrero, M, Sante Fornasiero, M, Santes Jasso, O, Santos Pereira, I, Santos Sousa, H, Saratzis, A, Sarmiento Alarcon, A, Saumtally, T, Sayyed, R, Schettino, M, Schleimer, L, Schmidt, T, Schondffelt, K, Schwab, M, Scott, A, Searle, H, Sebopelo, L, Seeglier, B, Seishima, R, Semenvov, D, Senent-Boza, A, Sepulveda, J, Serenari, M, Serrano Navidad, M, Sert, I, Sewart, E, Sgro, A, Shadrina, V, Shah, K, Shahid, F, Shalaby, M, Shankar, B, Shapiro, J, Sharma, L, Sheel, A, Shenfine, A, Shenoy, S, Sherif, A, Shetty, N, Shetty, R, Sia, T, Sichimba, D, Siddique, H, Siddiqui, I, Simkens, G, Simoe, J, Simon, H, Sinan, L, Singh, T, Singh, K, Singh, Y, Sinha, L, Siragusa, L, Sluckin, T, Smart, Y, Smith, H, Smith, K, Smits, L, Sneep-Van Kessel, C, Sohrabi, C, Solorzano Pineda, O, Soma, A, Sooriyapiragasam, L, Soreide, K, Sparavigna, M, Spence, R, Spencer, N, Spiers, H, Spinelli, A, Sprakel, J, Sravanam, S, Srinivasan, M, Srinivasan, R, Staniszewska, A, Stanworth, S, Stasinos, K, Steele, R, Steinholt, I, Steinruecke, M, Stephen, B, Stijns, J, Still, M, Stupalkowska, W, Subba, S, Subbotin, V, Sucharitkul, P, Sudarsanam, A, Sudhamsh Reddy, D, Suhardja, T, Suliman, M, Sund, M, Sunilkumar, A, Suresh, N, Sussmes, S, Sutton, P, Syltern, J, Taha, A, Takamizawa, Y, Takoutsing Dongmo, A, Tamas, T, Tan, L, Tan, J, Tan, K, Tan, E, Tan Yong Hui, A, Tanase, A, Tariverdiev, A, Tasnem, A, Tatar, C, Tay, E, Tejedor, P, Tesfaye, G, Tetinou, F, Thorpe, C, Thyo, A, Tlelo Amastal, D, Tolani, M, Tolga Saracoglu, K, Tolgyes, T, Tong, J, Torrent Jansa, L, Toscano Igartua, S, Tovani Palone, M, Traff, H, Trevis, J, Tummers, W, Tur, A, Turchenko, I, Uche, V, Uddin, A, Udonsak, N, Ullah, M, Urbonas, T, Uwins, C, Uy Magadia, E, Uzair Qureshi, A, Uzun, K, Vadim, P, Valarche, G, Valdez Gonzalez, R, Vallee, M, Van Beek, D, Van Dalen, A, Van Den Hondel, D, Van Der Stok, E, Van Dorp, M, Van Oostendorp, S, Van Praag, E, Van Rees, J, Van Silfhout, L, Varga, Z, Varghese, S, Varghese, C, Varghese, J, Vasilica, A, Vasquez Ojeda, X, Vega, E, Vehler, S, Venchiarutti, R, Vengatesan, S, Venn, M, Verma, D, Vianey Partida Nava, G, Victoria, D, Vieira, P, Vilar Alvarez, M, Vinci, D, Viscasillas Pallas, G, Viswanath, M, Vivanco, J, Vizcaya Rodriguez, V, Vo, J, Volchanski, D, Voron, T, Voronovskyi, Y, Vu, J, Wadhwa, M, Wadhwa, S, Wagner, G, Wallace, M, Wang, Y, Wang, J, Wani, A, Wanigasooriya, K, Wanjara, S, Wanjiku, N, Warner, C, Wei Leow, T, Weiser, T, Weisters, M, Wellington, M, Wells, C, Wenzelberg, C, Wettstein, D, Wezel, A, Wheldon, L, Widmer, L, Wilson, M, Wigmore, S, Wijayaratne, T, Wijeyaratne, M, Wijnhoven, B, Wilkin, R, Williams, E, Willis, F, Winter, D, Wirsik, M, Wishah, B, Wong, G, Wong, W, Wong, K, Worku, D, Wright, E, Wright, J, Wroe Wright, O, Xenacki, S, Xia, W, Xu, W, Xu, Z, Yalcinkaya, A, Yang, W, Yang, P, Yanishev, A, Yanzon De La Torre, A, Yao, H, Yaqoob, E, Yen Ling Quake, S, Yeo, D, Yeom, B, Yershov, D, Yiasemidou, M, Yildiz, A, Yiu, A, Yoav, M, Yong, E, Yoshimura, R, Younis, M, Younis Ringshawl, Z, Youssef, M, Yue, Y, Yuen, S, Yuldashev, R, Yurttas, C, Yves, B, Zaborowski, A, Zackeri, R, Zafar, A, Zahra, W, Zaidi, A, Zainudin, S, Zakeri, R, Zamora, I, Zamora, A, Zawistowski, M, Zbikowska, G, Zegers, W, Zehra, S, Zeyra, A, Zhagniyev, Z, Zhukova, L, Zivanovic, M, Zmuc, J, Zope, M, Zubayraeva, A, Zucker, B, Aguilera-Arévalo, M -L, Aguirre Salamanca, E J, Al-Asali, N, Altıner, S, Alvarez Lozada, L A, Anastasopoulos, N -A, Andrés Urrutia, J, Angarita, K -L, Ángel FreirÍa Eiras, M, Anwar, M A, Apampa, T O, Archila Godínez, M I, Arteaga Asensio, P C, Bankole, N D A, Barreras Espinoza, J A, Bhatti, M T, Bonci, E -A, Borunda Escudero, G E, Bosco, S J, Boström, P, Botelho de Alencar Ferreira Cruz, P, Caicedo, E Y, Castañeda Ramírez, O A, Catalán, V, Chen, H W, Chowdhury, M R, Chua, H W, Coelen, R -J, Colás-Ruiz, E, Correia de Sá, T, Coşgun Acar, N, D’Alessio, R, David, S O, de Andres Crespo, M, de Berker, H, de Dieu Ngo, P, de la Caridad Espinosa Luis, R, de Lacy, B, de Montserrat Medina Sifuentes, A, del Rio, C, Demirbaş, I, Díaz, Á, Diaz del Gobbo, G, Diaz-Castrillon, C, du Plessis, M C, Dumbrava, B -D, Efrén Lozada Hernández, E, Fernández Alberti, J, Forero, M P, Fredriksson, Å, Fülöp, A, Gatan, R G, Gortázar, S, Gregório, L, Grüter, A, Gülçek, E, Hafeez Bhatti, A B, Hoh, S M, Hölmich, E, Hüttner, F, Alhasan, A J M S, Perez Rivera, C J, Jácome, F, Jariod-Ferrer, Ú, José, J, José Núñez Ju, J, José Pizarro, M, Khan, M F, Kırımtay, B, Kmezić, S, Koëter, T, König, D, Leyva Moraga, F A, Li, H L, Londoño, M A, Lopes de Freitas, R, López, A I, Mafla Herrería, C A, Manzano Nuñez, R, Marín, D, Martín Martín, G, Masior, Ł, Möckli, B, Mohamed, H M, Mohammad, S A, Mohammed, T O, Montcusí Ventura, B, Mora-Guzmán, I, Morán, R A R, Morera, Á, Moss, J -L, Moyón, M, Müller, P, Muñoz, F, Muñoz, E, Muñoz, A, Muñoz Balderas, D C, Ng, C E, Fhearaigh, R N, Nikolousakis, T -K, Kristensen, H Ø, O’Brien, L, O’Brien, S, O’Reilly, J, O’Rourke, S, O’Sullivan, M, O’Dwyer, M, Oh, K E, Öhlberger, L, Ölçüm, M, Oscullo Yepez, J J, Osei-kuffour, N, Ottlakán, A, Pavan Kumar, O M, Peña Gallardo, M T, Peña Velazquez, A, Pérez-Sánchez, L E, Pompeu Sá, M, Ponniah, H S, Ponte de Sousa, X, Portilla, A L, Pulido Segura, J A, Quimbaya Rodríguez, A S, Racoviţă, A, Rahiri, J -L, Rey Chaves, C E, Roalsø, M, Rodríguez, F, Rodriguez, M C, Ruiz-Úcar, E, Rutegård, M, Sá-Marta, E, Sam, Z H, Emile, Sameh H, Sánchez Fonseca, S, Sgrò, A, Sia, T C, Smart, Y W, Sneep-van Kessel, C, Solórzano Pineda, O, Stephen, B -J, Takoutsing Dongmo, A B, Tamás, T, Tan, J L, Thyø, A, Tölgyes, T, Torrent Jansà, L, Tovani Palone, M R, Valdez Gonzalez, R A, van Beek, D -J, van Dalen, A S, van den Hondel, D, van der stok, E, van Dorp, M, van Oostendorp, S, van Praag, E, van Rees, J, van Silfhout, L, Vasilica, A -M, Vásquez Ojeda, X, Vilar Alvarez, M E, Viscasillas Pallàs, G, Vizcaya Rodríguez, V, Wang, Y Y, Wellington, M J, Wirsik, M M, Wong, W J, Wong, K -Y, Wright, O Wroe, Yang, P -C, Yanzon de la Torre, A, Younis, M U, Zamora, A T, and Surgery
Subjects: Adult, Male, medicine.medical_specialty, Biomedical Research, Coronavirus disease 2019 (COVID-19), International Cooperation, Practice Patterns, Commission, Global Health, Health Services Accessibility, Perioperative Care, Education, Surgeon, COVID-19, surgery, perioperative care, Medical, Pandemic, Humans, Medicine, Practice Patterns, Physicians', Graduate, Pandemics, Surgeons, Health Resource, Infection Control, Physicians', Surgical Procedures, business.industry, General surgery, Middle Aged, Operative, Education, Medical, Graduate, Surgical Procedures, Operative, Perioperative care, Health Resources, Surgery, Female, business, Human
Abstract: Background Coronavirus disease 2019 (COVID-19) was declared a pandemic by the WHO on 11 March 2020 and global surgical practice was compromised. This Commission aimed to document and reflect on the changes seen in the surgical environment during the pandemic, by reviewing colleagues’ experiences and published evidence. Methods In late 2020, BJS contacted colleagues across the global surgical community and asked them to describe how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had affected their practice. In addition to this, the Commission undertook a literature review on the impact of COVID-19 on surgery and perioperative care. A thematic analysis was performed to identify the issues most frequently encountered by the correspondents, as well as the solutions and ideas suggested to address them. Results BJS received communications for this Commission from leading clinicians and academics across a variety of surgical specialties in every inhabited continent. The responses from all over the world provided insights into multiple facets of surgical practice from a governmental level to individual clinical practice and training. Conclusion The COVID-19 pandemic has uncovered a variety of problems in healthcare systems, including negative impacts on surgical practice. Global surgical multidisciplinary teams are working collaboratively to address research questions about the future of surgery in the post-COVID-19 era. The COVID-19 pandemic is severely damaging surgical training. The establishment of a multidisciplinary ethics committee should be encouraged at all surgical oncology centres. Innovative leadership and collaboration is vital in the post-COVID-19 era.
Published: 2021

42. THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY

Author: L. G. Zhukova, E. K. Shoua, E. G. Slavina, M. A. Okruzhnova, N. Т. Dzhgamadze, Z. G. Kadagidze, V. A. Nurtdinova, A. I. Chertkova, and A. A. Borunova
Subjects: 0301 basic medicine, Oncology, medicine.medical_specialty, Cellular immunity, overall survival, medicine.medical_treatment, Immunology, chemotherapy, peripheral lymphocyte subpopulations, 03 medical and health sciences, disease progression, 0302 clinical medicine, Internal medicine, medicine, Immunology and Allergy, In patient, Triple-negative breast cancer, Chemotherapy, business.industry, RC581-607, 030104 developmental biology, triple negative breast cancer, 030220 oncology & carcinogenesis, Immunologic diseases. Allergy, business, progression-free survival
Abstract: Chemotherapy is among the primary methods of treating advanced breast cancer. It was shown that clinical efficacy of various chemotherapeutic agents in many cases depends not only on their direct cytostatic and/or cytotoxic effect upon tumor cells, but also on their ability to modulate phenotype of the tumor cells and to influence anti-tumor immune response. Initial state of the immune system and its response to treatment is crucial. Antitumor response involves cells of innate and adaptive immunity (NK, NKT, T cells). These populations are heterogeneous and contain, e.g., cells with antitumor activity and regulatory (suppressor) cells that suppress immune response and promote tumor progression. The aim of this work was to determine the relationship between the initial state of cellular immunity of patients suffering from locally advanced breast cancer with triple negative phenotype, and clinical effect of chemotherapy (cisplatin + doxorubicin/paclitaxel), and studying effects of the therapy upon subpopulation profiles of peripheral blood lymphocytes in the patients. We registered the terms of the disease progression as well as overall survival and progression-free survival. The disease progressed in 25 of 53 cases (47.2%) whereas 28 of 53 patients (52.8%) remained progression-free. The observation period was 35.5 months. Laboratory examination of the patients included immunophenotyping of peripheral blood lymphocytes and determination of NK cell cytotoxic activity before and after chemotherapy. Percentages of effectors and regulatory lymphocyte populations were determined. The results obtained showed that, for some lymphocyte subsets, the pre-treatment differences of cell percentage deviations from control were found between the progression-free groups and patients with progression of the disease. The differences in percentages of NKT cells and lymphocytes expressing CD25 activation marker proved to be most significant. Decreased number of NKT cells and activated CD25+ lymphocytes prior to chemotherapy was associated with increased probability of disease progression. Reduced percentage of NKT cells against control was observed in 56% of patients from the progression group (PD), and only 21.4% in the group free of disease progression (DF). [OR = 4.6 (95% CI 1.4 to 15.4)]. Percentage of CD25+ lymphocytes was decreased from 68.2% in the PD group, and 28.6% for DF patients [OR = 5.4 (95% CI 1.6-18.1)]. We studied relationships between the overall survival (OS) and percentage of perforin-containing NK, NKT, and T cells, and mean perforin fluorescence density (PFD) in these lymphocyte subsets in 26 of the 53 patients before treatment. A statistically significant positive correlation was revealed between OS and perforin PFD in all the three cell populations under study. Normalization of the parameters altered before treatment, and an increase of T cell numbers was observed in the disease-free patients.
Published: 2018

43. METASTASIS OF RENAL CANCER TO BREAST: DESCRIPTION OF CLINICAL CASE

Author: E. V. Chernova, V. A. Khaylenko, L. G. Zhukova, A. G. Abdullaev, D. V. Komov, L. N. Lyubchenko, A. V. Khaylenkо, N. E. Kudashkin, and D. A. Burov
Subjects: medicine.medical_specialty, Urology, medicine.medical_treatment, renal cancer, metastasis in breast, Metastasis, Surgical removal, nephrectomy, medicine, Radiology, Nuclear Medicine and imaging, Surgical treatment, Chemotherapy, business.industry, Cancer, medicine.disease, Nephrectomy, medicine.anatomical_structure, Oncology, Nephrology, Medicine, Surgery, Radiology, Pancreas, business, Clear cell
Abstract: The main method of treatment of local stages of clear cell renal cancer is surgical. The question of conducting adjuvant irradiation and chemotherapy after radical operations is open. Patients with solitary distant metastases and a favorable prognosis may become candidates for surgical treatment. Surgical removal of isolated solitary metastases allows to achieve 35–60 % of 5-year overall survival. The patient, observed in N.N. Blokhin National Medical Research Center of Oncology with metastasis of renal cancer in the pancreas, and then in the breast is an extremely rare clinical case presented in this article.
Published: 2018

44. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer]

Author: I V, Kolyadina, L E, Zavalishina, I P, Ganshina, Yu Yu, Andreeva, G A, Frank, O O, Gordeeva, L G, Zhukova, A A, Meshcheryakov, N A, Savelov, E A, Tuzova, D A, Morozov, and I V, Poddubnaya
Subjects: Adult, Receptor, ErbB-2, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Gene Amplification, Humans, Breast Neoplasms, Female, Middle Aged, Trastuzumab, Mastectomy, Neoadjuvant Therapy, Neoplasm Staging
Abstract: To evaluate the influence of clinical and morphological factors and HER2 copy numbers on pathologic complete response (pCR) rates in patients with HER2-positive stage II-III breast cancer (BC).Treatment results were studied in 73 patients with HER2-positive Stage II-III BC, who received treatment at the N.N. Blokhin National Medical Research Center of Oncology in 2015 to 2018. Treatment included neoadjuvant chemotherapy (NACT) with HER2-blockade and radical surgery followed by the evaluation of a pathologic response in the primary tumor and regional lymph nodes. The patients` age varied from 29 to 71; its median was 51.5; 45.2% of patients had primary operable stages (TA breast pCR (bpCR) was achieved in 57.4% patients; bpCR and lymph node CR (lnCR) were noted in 48.9% patients. The rates of bpCR significantly depended on female age, chemotherapy regimen, addition of Pertuzumab, and HER2 copy number. That of bpCR in women less than 35 years of age, in those aged 36-50 years, and in those aged older than 50 years was 22.2, 57.7 and 71.9%, respectively (p=0.026). The maximum bpCR rate observed with the TCH±P regimen was 80.0%, that with anthracycline-containing regimes was 52.8% (p=0.045), and the addition of Pertuzumab increased complete response rates up to 88.9% (that with Trastuzumab was 54.2% (p=0.049). The relationship of bpCR rates to the detection of cluster amplification turned out to be highly significant (81% in its detection and 48.9% in its absence (p=0.013). In addition, clustered HER2 amplification was the only significant predictive factor for complete regression in the primary tumor and lymph nodes: in its presence, the tpCR rate reached 68.8% versus 38.7%.Clustered amplification of the HER2 gene is the most significant factor of sensitivity to anti-HER2 therapy for Stage II-III BC, and is associated with the maximum rate of both bpCR and total pCR. Further study of this factor may assist in optimizing the treatment algorithm for HER2 + BC.Оценить влияние клинико-морфологических факторов, а также количества копий гена HER2 на частоту достижения полного патоморфоза (pCR) у больных с HER2+ раком молочной железы (РМЖ) II-III стадии.Изучены результаты лечения 73 больных РМЖ II-III стадии, получивших комплексное лечение в ФГБУ 'НМИЦ онкологии им. Н.Н. Блохина' с 2015 по 2018 г. (неоадъювантная химиотерапия (НАХТ) с анти-HER2-блокадой и радикальное хирургическое лечение с оценкой лечебного патоморфоза первичной опухоли и регионарных лимфатических узлов). Возраст пациенток составил от 29 лет до 71 года, медиана - 51,5 года; 45,2% пациенток имели первично-операбельные стадии (T1-3N0-1) и 54,8% - местно-распространенные. Степень анаплазии G2-G3 была у всех больных, люминальный HER2-положительный РМЖ был диагностирован у 41,1% пациенток, у 58,9% опухоли были гормононегативными; Ki-67 ≥20% имели 91,5% пациенток. Предоперационная системная терапия включала антрациклинсодержащие режимы у 75,3% женщин (4 цикла химиотерапии по схеме АС с переключением на 4 цикла паклитаксела в дозе 175 мг/мПолный регресс опухоли молочной железы (bpCR) отмечен у 57,4%, полный ответ в опухоли молочной железы и в лимфатических узлах (tpCR) - в 48,9% случаев. Частота достижения bpCR значимо зависела от возраста женщин, режима химиотерапии, добавления к лечению пертузумаба и количества копий гена HER2. Частота достижения bpCR у женщин до 35, 36–50 и старше 50 лет составила 22,2, 57,7 и 71,9% соответственно; p=0,026. Максимальная частота bpCR отмечена при применении режима TCH±Р - 80%, при антрациклинсодержащих режимах 52,8%; p=0,045, добавление пертузумаба увеличивало частоту полных ответов до 88,9% (при применении трастузумаба 54,2%; p=0,049). Высокодостоверной оказалась зависимость частоты bpCR от обнаружения кластерной амплификации (81% при ее обнаружении и 48,9% при ее отсутствии; p=0,013). Кроме того, кластерная амплификация гена HER2 была единственным значимым фактором-предиктором достижения полного регресса первичной опухоли и лимфатических узлов: при ее наличии частота tpCR достигла 68,8% против 38,7%.Наличие кластерной амплификации гена HER2 является наиболее значимым фактором чувствительности к анти-HER2-терапии при РМЖ II-III стадии, ассоциируется с максимальной частотой достижения полного лечебного патоморфоза как первичной опухоли в молочной железе, так и регионарных метастазов. Дальнейшее изучение данного фактора может помочь оптимизации лечебного алгоритма при HER2 + РМЖ.
Published: 2019

45. The prospects for cisplatin and nab-paclitaxel combination therapy in patients with pre-treated triple-negative breast cancer. Description of the clinical case

Author: E. V. Lubennikova, L. G. Zhukova, I. R. Suslova, and K. S. Bardovskaya
Subjects: Cisplatin, Oncology, medicine.medical_specialty, Combination therapy, business.industry, General Medicine, taxanes, nab-paclitaxel, triple negative breast cancer, Internal medicine, medicine, Medicine, In patient, Clinical case, business, Triple-negative breast cancer, Nab-paclitaxel, medicine.drug
Abstract: Molecular and biological features of triple negative breast cancer (TN BC) determine the limited possibilities of systemic therapy and, as a consequence, the more aggressive course of the disease. Taxanes are one of the most effective chemotherapies used in breast cancer therapy. The special form of paclitaxel nab-paclitaxel makes it possible to obtain an objective and a subjective effect, which is especially important in the pre-treated patients. In addition, the drug has a favourable safety profile and a well-controlled toxicity.The article contains a review of the literature on the prospects for the use of nab-paclitaxel in breast cancer, especially in its triple negative version, and a description of the clinical case of therapy with a combination of cisplatin and nab-paclitaxel in a young patient with BRCA-1-associated TN breastcancer.
Published: 2018

46. The use of regorafenib in patients with disseminated gastrointestinal stromal tumours. A review of the literature. A clinical case

Author: D. A. Filonenko, S. V. Petukhova, E. I. Khatkova, K. A. Vorontsova, E. I. Chichikov, B. M. Medvedeva, and L. G. Zhukova
Subjects: stromal tumours of the gastrointestinal tract, Oncology, medicine.medical_specialty, multikinase inhibitors, GiST, Sunitinib, business.industry, Imatinib, General Medicine, Disease, Gene mutation, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Regorafenib, medicine, regoraphanib, Medicine, Disseminated disease, business, neoplasms, Tyrosine kinase, medicine.drug
Abstract: The survival of patients even with disseminated disease reached 7–8 years after introduction of imatinib and sunitinib for the treatment of gastrointestinal stromal tumours (GIST) into everyday clinical practice. These drugs efficacy is largely determined by the presence and any mutations of C-KIT and PDGFR genes. It was established that new mutations appear in most tumours against the background of tyrosine kinase inhibitors therapy, which causes the development of secondary resistance and the progression of the disease in most cases. The search for opportunities to overcome the newly developed or initially existing resistance caused by different gene mutations continues to be of vital importance. One of such drugs is regorafenib, which has demonstrated antitumour activity against progression on imatinib and/or sunitinib. The paper reviews the studies of the efficacy of regoraphanib in patients with disseminated GIST, taking into account the presence and any mutations of C-KIT and PDGFR genes, and presents a description of their own clinical case of prolonged use of the drug in a patient who have received earlier both imatinib and sunitinib.
Published: 2018

47. Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia

Author: N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, and A. A. Fedenko
Subjects: Oncology, Chemotherapy, medicine.medical_specialty, Second line treatment, ramucirumab, business.industry, medicine.medical_treatment, second line treatment, General Medicine, Gastroesophageal Junction Adenocarcinoma, Second line chemotherapy, Ramucirumab, paclitaxel, Safety profile, Gastric adenocarcinoma, Internal medicine, Combination group, Medicine, business, advanced gastric cancer
Abstract: Background.Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In April 2014, the FDA approved ramucirumab as a single agent or in combination with paclitaxel for treatment of advanced gastric or gastroesophageal junction adenocarcinoma that has progressed on or after prior fluoropyrimidineor platinum containing chemotherapy based on data of REGARD and RAINBOW trials.Materials and Methods: From June 2016 to 15Jan 201837 pts with advanced GC were treated with ramucirumabin the second line treatment as single agent (11 pts) or in combination with paclitaxel (26 pts) in N.N.Blokhin National medical research center of oncology.Results: edian PFS (MPFS) and median OS (MOS) was 1,8 and 7,6 mons for monotherapy group. For combination group MPFS was 4,0mons, MOS -10,6 mons. Ramucirumab had an acceptable safety profileConclusions:ur data are similar to the data of international randomized trials.
Published: 2018

48. Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?

Author: T E Tikhomirova, L G Zhukova, Inna P. Ganshina, O E Kondratyeva, and E. I. Khatkova
Subjects: Oncology, her2-possitive, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, lcsh:RC254-282, law.invention, Breast cancer, breast cancer, Randomized controlled trial, law, Trastuzumab, Internal medicine, Medicine, skin and connective tissue diseases, Cardiotoxicity, Chemotherapy, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical trial, Regimen, trastuzumab, business, Adjuvant, medicine.drug
Abstract: According to the results of the conducted studies in the early 2000’s, adjuvant trastuzumab for 1 year has been admitted the gold standard since 2006. However, the high cost of treatment and the increasing of the risk of cardiotoxicity have led to new clinical trials concerning the short-course trastuzumab regimen. The study deals with the results of the number of the largest randomized trials associated with the comparison of 6 months (the PHARE trial and the HORG study), 9 weeks (the Short-HER study and the SOLD study) and 12 months duration of adjuvant trastuzumab therapy in combination with chemotherapy in patients with HER2-possitive early breast cancer. Today, none of the studies has shown statistically significant evidence of the possibility to reduce the duration of adjuvant trastuzumab therapy.
Published: 2018

49. Clinical features and results of surgical treatment of bilateral renal cancer

Author: M. I. Komarov, V. B. Matveev, L. G. Zhukova, I. G. Komarov, and V. A. Chernyaev
Subjects: organ preservation surgery, medicine.medical_specialty, Urology, Disease, Gastroenterology, Renal cell carcinoma, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, synchronous cancer, business.industry, Incidence (epidemiology), bilateral renal cancer, metachronous cancer, Cancer, medicine.disease, Oncology, Nephrology, Concomitant, Clear cell carcinoma, Medicine, Surgery, Metachronous cancer, business, Kidney cancer
Abstract: Renal cancer morbidity grows in most of the developed countries. Incidence of bilateral renal cell carcinoma, per various authors, amounts to 2–6 % of all cases of this disease. The study included 160 patients with bilateral kidney cancer who received surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology in the period from 1996 to 2014. Median follow-up duration for all patients included in the analysis was 81.05 ± 46.7 months. In our study, the groups for synchronous and metachronous cancer were equal (n = 80) and constituted 3.5 % of all cases of kidney cancer. For synchronous and metachronous cancer types, the most common concomitant disease was arterial hypertension. The most common morphological variant for the first, as well as the second, kidney tumor was clear cell carcinoma. Smoking and ischemic heart disease as a concomitant pathology negatively affected relapse-free and overall survival. Overall 5-year survival for synchronous renal cancer was 84.4 ± 4.2 %, for metachronous – 64.8 ± 9.3 %.
Published: 2018

50. EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

Author: E. V. Lubennikova, I. P. Ganshina, A. N. Lud, D. V. Komov, I. V. Kolyadina, Y. V. Vishnevskaya, I. K. Vorotnikov, D. L. Stroyakovsky, N. A. Savelov, V. F. Semiglazov, А. G. Manikhas, А. V. Osheychik, T. B. Strelnikova, K. R. Zeynalova, and L. G. Zhukova
Subjects: Oncology, medicine.medical_specialty, medicine.medical_treatment, Breast cancer, Trastuzumab, Internal medicine, HER2 Positive Breast Cancer, her2-positive breast cancer, medicine, Effective treatment, In patient, neoadjuvant therapy, skin and connective tissue diseases, Vein, neoplasms, Neoadjuvant therapy, business.industry, General Medicine, medicine.disease, trastuzumab, medicine.anatomical_structure, Tolerability, Medicine, business, medicine.drug
Abstract: The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in Russian population showed the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.
Published: 2017

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

104 results on '"L G Zhukova"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources